12 September 2022
EMA/CHMP/700565/2022
Human Medicines Division

# Committee for medicinal products for human use (CHMP)

## Draft agenda for the meeting on 12-15 September 2022

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

12 September 2022, 13:00 – 19:30, virtual meeting/room 1C

13 September 2022, 08:30 – 19:30, virtual meeting/room 1C

14 September 2022, 08:30 – 19:30, virtual meeting/room 1C

15 September 2022, 08:30 – 15:00, virtual meeting/room 1C

**Health and safety information**

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

**Disclaimers**

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

**Note on access to documents**

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

**Official address** Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
**Address for visits and deliveries** Refer to www.ema.europa.eu/how-to-find-us
**Send us a question** Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

# Table of contents

# 1. Introduction

## 1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 12-15 September 2022. See September 2022 CHMP minutes (to be published post October 2022 CHMP meeting).

## 1.2. Adoption of agenda

CHMP agenda for 12-15 September 2022.

## 1.3. Adoption of the minutes

CHMP minutes for 18-21 July 2022 and 16-19 August 2022 written procedure.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 05 September 2022.

# 2. Oral Explanations

## 2.1. Pre-authorisation procedure oral explanations

### 2.1.1. spesolimab - EMEA/H/C/005874

treatment of flares in adult patients with generalised pustular psoriasis

Scope: Possible oral explanation

**Action**: Oral explanation to be held on 14 September 2022 at 14:00

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on 24.02.2022.

## 2.2. Re-examination procedure oral explanations

### 2.2.1. Tuznue - trastuzumab - EMEA/H/C/005066 / Hervelous - trastuzumab - EMEA/H/C/005880

Prestige Biopharma Belgium, treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Oral explanation

**Action**: Oral explanation to be held on 13 September 2022 at 14:00

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

Opinion adopted on 19.05.2022. List of Outstanding Issues adopted on 27.01.2022, 25.03.2021, 10.12.2020. List of Questions adopted on 19.09.2019.

See 3.5

## 2.3. Post-authorisation procedure oral explanations

No items

## 2.4. Referral procedure oral explanations

No items

# 3. Initial applications

## 3.1. Initial applications; Opinions

### 3.1.1. nirsevimab - PRIME - EMEA/H/C/005304

prevention of RSV lower respiratory tract infection.
Immunise infants from birth entering their first Respiratory Syncytial Virus (RSV) season for the prevention of RSV lower respiratory tract disease.

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 19.07.2022. List of Questions adopted on 17.05.2022.

### 3.1.2. sutimlimab - Orphan - EMEA/H/C/005776

Genzyme Europe BV; treatment of haemolysis in adult patients with cold agglutinin disease (CAD)

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 23.06.2022. List of Questions adopted on 24.02.2022.

### 3.1.3. maribavir - Orphan - EMEA/H/C/005787

Takeda Pharmaceuticals International AG Ireland Branch; treatment of cytomegalovirus (CMV) infection

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 23.06.2022, 22.04.2022. List of Questions adopted on 14.10.2021.

### 3.1.4. gozetotide - EMEA/H/C/005488

indicated for the identification of prostate-specific membrane antigen (PSMA)-positive lesions after radiolabelling with gallium-68

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on 24.02.2022.

### 3.1.5. melatonin - EMEA/H/C/005603

treatment of primary insomnia

Scope: Opinion

**Action**: For adoption

### 3.1.6. octreotide - Orphan - EMEA/H/C/005826

Amryt Pharmaceuticals DAC; treatment of acromegaly

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 16.12.2021.

### 3.1.7. mitapivat - Orphan - EMEA/H/C/005540

Agios Netherlands B.V.; treatment of pyruvate kinase deficiency

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 21.07.2022, 19.05.2022, 24.03.2022. List of Questions adopted on 11.11.2021.

### 3.1.8. sorafenib - EMEA/H/C/005921

treatment of hepatocellular carcinoma and renal cell carcinoma

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 11.11.2021.

### 3.1.9. teriflunomide - EMEA/H/C/005960

treatment of multiple sclerosis (MS)

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on 24.02.2022.

### 3.1.10. teriflunomide - EMEA/H/C/005962

treatment of multiple sclerosis (MS)

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 23.06.2022. List of Questions adopted on 27.01.2022.

### 3.1.11. teriparatide - EMEA/H/C/005793

treatment of osteoporosis

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 23.06.2022. List of Questions adopted on 20.05.2021.

### 3.1.12. ranibizumab - EMEA/H/C/005617

treatment of neovascular age-related macular degeneration (AMD)

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 23.06.2022. List of Questions adopted on 27.01.2022.

### 3.1.13. loncastuximab tesirine - Orphan - EMEA/H/C/005685

ADC Therapeutics (NL) B.V.; treatment of adult patients with relapsed or refractory large B-cell lymphoma

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on 24.02.2022.

## 3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

### 3.2.1. dabigatran etexilate - EMEA/H/C/005639

prevention of venous thromboembolic events

Scope: List of outstanding issues

**Action**: For adoption

List of Outstanding Issues adopted on 23.06.2022, 24.02.2022. List of Questions adopted on 12.11.2020.

### 3.2.2. tabelecleucel - PRIME - Orphan - ATMP - EMEA/H/C/004577

Atara Biotherapeutics Ireland Limited; treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV$^+$ PTLD)

Scope: List of outstanding issues

**Action**: For information

List of Questions adopted on 18.03.2022.

### 3.2.3. abaloparatide - EMEA/H/C/005928

treatment of osteoporosis

Scope: List of outstanding issues

**Action**: For adoption

List of Questions adopted on 24.03.2022.

### 3.2.4. maralixibat - Orphan - EMEA/H/C/005857

Mirum Pharmaceuticals International B.V.; Treatment of cholestatic liver disease in patients with Alagille syndrome (ALGS) 1 year of age and older

Scope: List of outstanding issues

**Action**: For adoption

List of Outstanding Issues adopted on 23.06.2022. List of Questions adopted on 27.01.2022.

### 3.2.5. miglustat - Orphan - EMEA/H/C/005695

Amicus Therapeutics Europe Limited; treatment of adults aged 18 years and older with a confirmed diagnosis of Pompe disease

Scope: List of outstanding issues

**Action**: For adoption

List of Questions adopted on 24.03.2022.

### 3.2.6. pemetrexed - EMEA/H/C/005848

treatment of malignant pleural mesothelioma and non-small cell lung cancer

Scope: List of outstanding issues

**Action**: For adoption

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 16.12.2021.

### 3.2.7. pirfenidone - EMEA/H/C/005862

treatment of Idiopathic Pulmonary Fibrosis (IPF)

Scope: List of outstanding issues

**Action**: For adoption

List of Questions adopted on 24.03.2022.

### 3.2.8. cipaglucosidase alfa - Orphan - EMEA/H/C/005703

Amicus Therapeutics Europe Limited; treatment of adults aged 18 years and older with a confirmed diagnosis of Pompe disease

Scope: List of outstanding issues

**Action**: For adoption

List of Questions adopted on 24.03.2022.

### 3.2.9. palovarotene - Orphan - EMEA/H/C/004867

Ipsen Pharma; Treatment of fibrodysplasia ossificans progressiva

Scope: List of outstanding issues

**Action**: For adoption

List of Questions adopted on 16.09.2021.

### 3.2.10. sugammadex - EMEA/H/C/005935

reversal of neuromuscular blockade induced by rocuronium or vecuronium

Scope: List of outstanding issues

**Action**: For adoption

List of Questions adopted on 24.03.2022.

### 3.2.11. vadadustat - EMEA/H/C/005131

Treatment of anaemia

Scope: List of outstanding issues

**Action**: For adoption

List of Questions adopted on 24.03.2022.

## 3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

### 3.3.1. aflibercept - EMEA/H/C/006022

treatment of age-related macular degeneration (AMD) and visual impairment

Scope: List of questions

**Action**: For adoption

### 3.3.2. polihexanide - Orphan - EMEA/H/C/005858

SIFI SPA; For the treatment of acanthamoeba keratitis

Scope: List of questions

**Action**: For adoption

### 3.3.3. niraparib / abiraterone acetate - EMEA/H/C/005932

treatment of adult patients with prostate cancer

Scope: List of questions

**Action**: For adoption

### 3.3.4. ferumoxytol - EMEA/H/C/005974

intravenous treatment of iron deficiency anaemia (IDA)

Scope: List of questions

**Action**: For adoption

### 3.3.5. glofitamab - Orphan - EMEA/H/C/005751

Roche Registration GmbH; treatment of diffuse large B-cell lymphoma

Scope: List of questions

**Action**: For adoption

### 3.3.6. adagrasib - EMEA/H/C/006013

treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation

Scope: List of questions

**Action**: For adoption

### 3.3.7. lacosamide - EMEA/H/C/006047

treatment of epilepsy

Scope: List of questions

**Action**: For adoption

### 3.3.8. futibatinib - Orphan - EMEA/H/C/005627

Taiho Pharma Netherlands B.V.; treatment of cholangiocarcinoma

Scope: List of questions

**Action**: For adoption

### 3.3.9. mirikizumab - EMEA/H/C/005122

treatment of moderately to severely active ulcerative colitis

Scope: List of questions

**Action**: For adoption

### 3.3.10. sugammadex - EMEA/H/C/006046

reversal of neuromuscular blockade induced by rocuronium or vecuronium

Scope: List of questions

**Action**: For adoption

### 3.3.11. oteseconazole - EMEA/H/C/005682

treatment and prevention of recurrent vulvovaginal candidiasis (RVVC) including the acute episodes of RVVC in adult women

Scope: List of questions

**Action**: For adoption

## 3.4. Update on on-going initial applications for Centralised procedure

### 3.4.1. germanium (68Ge) chloride / gallium (68Ga) chloride - EMEA/H/C/005165

indicated for in vitro labelling of kits for radiopharmaceutical preparation

Scope: Letter by the applicant dated 06.09.2022 requesting an extension to the clock stop to respond to the list of questions issues adopted in December 2021.

**Action**: For adoption

List of Questions adopted on 16.12.2021.

### 3.4.2. ranibizumab - EMEA/H/C/005610

treatment of neovascular age-related macular degeneration in adults

Scope: Letter by the applicant dated 26.08.2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in April 2022.

**Action**: For adoption

List of Outstanding Issues adopted on 22.04.2022, 24.02.2022. List of Questions adopted on 16.09.2021.

### 3.4.3. gefapixant - EMEA/H/C/005884

treatment of refractory or unexplained chronic cough

Scope: Update on procedure, MWP's response to the CHMP list of questions

**Action**: For adoption

List of Outstanding Issues adopted on 27.01.2022, 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

### 3.4.4. gefapixant - EMEA/H/C/005476

treatment of refractory or unexplained chronic cough

Scope: Update on procedure, MWP's response to the CHMP list of questions

**Action**: For adoption

List of Outstanding Issues adopted on 27.01.2022, 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

## 3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

### 3.5.1. Hervelous - trastuzumab - EMEA/H/C/005880

Prestige Biopharma Belgium; treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Opinion

**Action**: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC), Duplicate of Tuznue

Opinion adopted on 19.05.2022.

See 2.2

### 3.5.2. Tuznue - trastuzumab - EMEA/H/C/005066

Prestige Biopharma Belgium; treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Opinion

**Action**: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

Opinion adopted on 19.05.2022. List of Outstanding Issues adopted on 27.01.2022, 25.03.2021, 10.12.2020. List of Questions adopted on 19.09.2019.

See 2.2

## 3.6. Initial applications in the decision-making phase

No items

## 3.7. Withdrawals of initial marketing authorisation application

No items

# 4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

## 4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

### 4.1.1. Betmiga - mirabegron - EMEA/H/C/002388/X/0039/G

Astellas Pharma Europe B.V.

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension application to introduce a new pharmaceutical form associated with new strength (8 mg/ml prolonged-release granules for oral suspension), grouped with a type II variation (C.I.6.a) to include treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years. The RMP (version 9.0) is updated in accordance."

**Action**: For adoption

List of Questions adopted on 22.04.2022.

### 4.1.2. Biktarvy - bictegravir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449/X/0040/G

Gilead Sciences Ireland UC

Rapporteur: Jean-Michel Race, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension application to introduce a new strength 30/120/15 mg. The extension application is grouped with a type II variation (C.I.6.a) to include paediatric indication: use in patients 2 years of age and older and weighing at least 14 kg. Sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 3.1) is updated in accordance."

**Action**: For adoption

List of Outstanding Issues adopted on 21.07.2022, 24.03.2022. List of Questions adopted on 14.10.2021.

### 4.1.3. Skyrizi - risankizumab - EMEA/H/C/004759/X/0020/G

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Jayne Crowe, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension application to:
- introduce a new pharmaceutical form (concentrate for solution for infusion), a new strength (600 mg) and a new route of administration (intravenous use).
- add a new strength of 360 mg (150 mg/ml) for risankizumab solution for injection (in cartridge) for subcutaneous use.

The above new presentations are indicated for the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable. The RMP (version 4.0) is updated in accordance."

**Action**: For adoption

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on 22.04.2022.

## 4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

### 4.2.1. Xofluza - baloxavir marboxil - EMEA/H/C/004974/X/0008/G

Roche Registration GmbH

Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Sonja Hrabcik

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (2 mg/ml granules for oral suspension) grouped with a type II variation (C.I.6.a) to include paediatric use (from 1 year and above). The paediatric indication is applicable to the new presentation (2 mg/ml granules for oral suspension) as well as all approved presentations (EU/1/20/1500/001 and 002). The RMP (version 2.0) is updated in accordance."

**Action**: For adoption

List of Questions adopted on 22.04.2022.

## 4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

No items

## 4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

## 4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

# 5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

## 5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

### 5.1.1. Adtralza - tralokinumab - EMEA/H/C/005255/II/0002

LEO Pharma A/S

Rapporteur: Jayne Crowe

Scope: "Extension of indication to include treatment of adolescent patients (12-17 years) for Adtralza based on final study LP0162-1334 (ECZTRA 6): a multicentre, randomised, double-blind, placebo-controlled study in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis to evaluate the efficacy and safety of tralokinumab monotherapy in this population group. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance."

**Action**: For adoption

Request for Supplementary Information adopted on 24.03.2022.

### 5.1.2. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - ATMP - EMEA/H/C/004731/II/0005

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli, CHMP Coordinator: Armando Genazzani, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of adult patients with Second-line (2L) Transplant Intended (TI) Large B-Cell Lymphoma (LBCL) for Breyanzi, based on interim analyses from pivotal study JCAR017-BCM-003; this is a global randomized multicentre Phase III Trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM); As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted."

**Action**: For adoption

### 5.1.3. Brukinsa - zanubrutinib - EMEA/H/C/004978/II/0002

BeiGene Ireland Ltd

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include treatment of adult patients with marginal zone

lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy, based on data from 88 patients with R/R MZL from 2 ongoing pivotal studies; study BGB-3111-214: A Phase 2, open-label, single-arm study designed to evaluate the safety and efficacy of zanubrutinib in patients with R/R MZL, and study BGB-3111-AU-003: A first-in-human, Phase 1/2, dose-escalation and selection, PK/pharmacodynamic, safety, and efficacy study in adult patients with R/R or treatment-naive B-cell malignancies. As a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated, and the Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted.
In addition, the MAH is requesting one additional year of market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action**: For adoption

Request for Supplementary Information adopted on 22.04.2022.

### 5.1.4. Cosentyx - secukinumab - EMEA/H/C/003729/II/0090

Novartis Europharm Limited

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension of indication to include treatment of Hidradenitis Suppurativa (HS) for Cosentyx, based on interim results from two Phase III studies CAIN457M2301 (SUNSHINE) and CAIN457M2302 (SUNRISE); These studies are ongoing, multi-center, randomized, double-blind, placebo-controlled, parallel group Phase 3 studies conducted to assess the short (16 weeks) and long-term (up to 52 weeks) efficacy and safety of two secukinumab dose regimens (Q2W or Q4W) compared to placebo in adult subjects with moderate to severe HS; As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2. of the SmPC are updated. The Package Leaflet is updated in accordance. Version 11 of the RMP has also been submitted."

**Action**: For adoption

### 5.1.5. Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0022

Daiichi Sankyo Europe GmbH

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include treatment of unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or withing 6 months of completing adjuvant chemotherapy. Patients with hormone receptor positive (HR+) breast cancer must additionally have received or be ineligible for endocrine therapy; for Enhertu, based on final results from study DS8201-A-U303 (DESTINY-Breast04). This is a Phase III, multicentre, randomised, open-label, active-controlled trial of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-antibody Drug Conjugate (ADC), versus treatment of physician's choice for HER2-low, unresectable and/or metastatic breast cancer subjects.
As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.4 of the RMP has also been submitted.
In addition, the Marketing authorisation holder (MAH) took the opportunity to update section 4.4 of the SmPC to update the dosing recommendation for corticosteroid treatment

(e.g. prednisolone) with a daily dose."

**Action**: For adoption

### 5.1.6. Epidyolex - cannabidiol - Orphan - EMEA/H/C/004675/II/0020

GW Pharma (International) B.V.

Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension of indication to include treatment with Epidyolex (monotherapy) as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS) for patients 2 years of age and older (without the restriction for use only in conjunction with clobazam), based on the previously generated data in patients treated without CLB in the LGS and DS pivotal studies re-evaluated in the context of the more recent evidence from study GWEP1521 in tuberous sclerosis complex (TSC). As a consequence, sections 4.1, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement editorial changes in the product information. Version 2.1 of the RMP has also been submitted."

**Action**: For adoption

### 5.1.7. Evusheld - tixagevimab / cilgavimab - EMEA/H/C/005788/II/0001

AstraZeneca AB

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen, based on interim results from study D8851C00001 (TACKLE); this is an ongoing, randomized, double-blind, placebo-controlled, multicenter study assessing the safety and efficacy of a single 600 mg dose of AZD7442 (× 2 IM injections) compared with matching placebo for the treatment of mild to moderate COVID-19 in non-hospitalised adults. As a consequence, sections 4.1, 4.2, 4.8, 4.9, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 2 Succession 1 of the RMP has also been submitted."

**Action**: For adoption

Request for Supplementary Information adopted on 23.06.2022.

### 5.1.8. Exparel liposomal - bupivacaine - EMEA/H/C/004586/II/0005

Pacira Ireland Limited

Rapporteur: Elita Poplavska, Co-Rapporteur: Margareta Bego, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension of indication to include children over 6 years old."

**Action**: For adoption

Request for Supplementary Information adopted on 19.05.2022, 16.12.2021.

### 5.1.9. Gavreto - pralsetinib - EMEA/H/C/005413/II/0002/G

Roche Registration GmbH

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include monotherapy treatment of adult and paediatric patients 12 years of age and older with locally advanced or metastatic RET-mutant medullary thyroid cancer for Gavreto; based on the efficacy and safety data obtained from the pivotal study BO42863 (ARROW). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. Furthermore, some minor changes to the PI have been implemented in line with the latest Anticancer Guidelines Recommendations. Extension of indication to include monotherapy treatment of adult and paediatric patients 12 years of age and older with locally advanced or metastatic RET fusion-positive thyroid cancer for Gavreto; based on the efficacy and safety data obtained from the pivotal study BO42863 (ARROW). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action**: For adoption

Request for Supplementary Information adopted on 23.06.2022, 24.03.2022.

### 5.1.10. Kerendia - finerenone - EMEA/H/C/005200/II/0001/G

Bayer AG

Rapporteur: Kristina Dunder, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include the treatment of chronic kidney disease (CKD) and for the prevention of cardiovascular (CV) events in adults with CKD (regardless of the stage of albuminuria) associated with type 2 diabetes, based on results from study 17530 (FIGARO-DKD); a randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care.
As a consequence, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC is being updated and the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make editorial changes in the SmPC. The updated RMP version 2.1 has also been submitted.
Update of the SmPC section 5.2 based on the results of study 21429, a phase 1 drug interaction study of finerenone with rosuvastatin. The CSR PH-42032 was already submitted within the response to Day 180 List of Outstanding Issues of the initial MAA.
Submission of the results of study 21325, a phase 1 bioequivalence study assessing BE between finerenone 2 x 10 mg tablets and 20 mg tablet in Japanese healthy male adult participants (required by the Japanese PMDA)."

**Action**: For adoption

Request for Supplementary Information adopted on 23.06.2022.

### 5.1.11. Lyumjev - insulin lispro - EMEA/H/C/005037/II/0014

Eli Lilly Nederland B.V.

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Mari Thorn

Scope: "Extension of indication to include the treatment of diabetes mellitus in adolescents and children aged 1 year and above, based on final results from study I8B-MC-ITSB; this is a pivotal Phase 3 study designed to evaluate the safety and efficacy of Lyumjev compared to Humalog in combination with basal insulin in children and adolescent patients with T1D. The study was designed to compare change in HbA1c as the primary endpoint. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial and linguistic changes in the SmPC and Package Leaflet.
As part of the application, the MAH is also requesting one additional year of market protection.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action**: For adoption

Request for Supplementary Information adopted on 21.07.2022, 22.04.2022.

### 5.1.12. Mircera - methoxy polyethylene glycol-epoetin beta - EMEA/H/C/000739/II/0092

Roche Registration GmbH

Rapporteur: Maria Concepcion Prieto Yerro

Scope: "Extension of indication to include treatment of paediatric patients from 3 months to less than 18 years of age requiring dialysis or not yet on dialysis and switching from another ESA to Mircera, based on final results from study NH19708; this is a single-arm, open-label, Phase II study of Mircera in patients aged 3 months to <18 years with CKD on dialysis or not yet on dialysis to generate PK, efficacy, and safety data for subcutaneous (SC) administration of Mircera. In addition, supportive data from studies NH19707, Modelling & Simulation study (study 3) and MH40258 were included. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to update the Instruction for Use in the Package Leaflet."

**Action**: For adoption

### 5.1.13. Nubeqa - darolutamide - EMEA/H/C/004790/II/0009

Bayer AG

Rapporteur: Alexandre Moreau, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Jan Neuhauser

Scope: "Extension of indication to include treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel, based on final results from study 17777 (ARASENS); this is a randomized, double-blind, placebo-controlled Phase 3 study designed to demonstrate the superiority of darolutamide in combination with docetaxel over placebo in combination with docetaxel in OS in patients with mHSPC. As a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package

Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. As part of the application, the MAH is also requesting one additional year of market protection.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action**: For adoption

Request for Supplementary Information adopted on 23.06.2022.

### 5.1.14. Revestive - teduglutide - Orphan - EMEA/H/C/002345/II/0054/G

Takeda Pharmaceuticals International AG Ireland Branch

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "Extension of indication to include patients from 4 months corrected gestational aged 1 year and above. Consequently, sections 4.1, 4.2, 4.8, 5.1 and 5.2 are updated. The package leaflet is updated accordingly. Update of annex II to amend the date of completion of the post-authorisation study. The MAH took the opportunity to also amend local representatives."

**Action**: For adoption

Request for Supplementary Information adopted on 22.04.2022, 11.11.2021.

### 5.1.15. Revolade - eltrombopag - EMEA/H/C/001110/II/0068

Novartis Europharm Limited

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension of indication to include treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) irrespective of time since initial diagnosis, based on an ad-hoc analysis of Study TAPER (CETB115J2411); an ongoing phase II, open-label, prospective, single-arm study in adult ITP patients who are refractory or relapsed after first-line steroids.
As a consequence, sections 4.1 and 5.1 of the SmPC have been updated.
In addition, the MAH took the opportunity to make some minor amendments in section 4.8 of the SmPC for increased consistency. An updated RMP version 54.0 has been submitted."

**Action**: For adoption

Request for Supplementary Information adopted on 22.04.2022.

### 5.1.16. TachoSil - human thrombin / human fibrinogen - EMEA/H/C/000505/II/0117

Corza Medical GmbH

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of children aged 1 month to 18 years, based on available bibliographical data, results from study TC-2402-040-SP which compared TachoSil with Surgicel Original as adjunct to primary surgical treatment in both adult and paediatric subjects, and results from study TC-019-IN; a prospective,

uncontrolled study in paediatric subjects. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the product information. Version 0.1 of the RMP has also been submitted."

**Action**: For adoption

### 5.1.17. Vaxneuvance - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/005477/II/0001

Merck Sharp & Dohme B.V.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of infants, children and adolescents from 6 weeks to less than 18 years of age for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media for Vaxneuvance, based on final results from 1 Phase II study (V114-008) and 7 Phase III studies (V114-023, V114-024, V114-025, V114-027, V114-029, V114-030, V114-031); these are interventional studies to evaluate the safety, tolerability and immunogenicity of V114 in healthy and immunocompromised infants, children and adolescents. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to include editorial changes in the product information. Version 1.1 of the RMP has also been submitted."

**Action**: For adoption

Request for Supplementary Information adopted on 21.07.2022, 22.04.2022.

### 5.1.18. Veklury - remdesivir - EMEA/H/C/005622/II/0035/G

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová

Scope: "Grouped application of two extensions of indication to include:
- treatment of paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) or other non-invasive ventilation at start of treatment, based on interim results from study GS-US-540-5823; a phase 2/3 single-arm, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Remdesivir in participants from birth to <18 years of age with COVID-19;
- treatment of paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19, based on data from 8 adolescent patients who were included in study GS-US-540-9012, which was initially assessed by the CHMP as part of procedure II/16 (Extension of indication to include treatment of adults).
As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet as well as the instructions for healthcare professionals have been updated accordingly. Version 3.2 of the RMP has also been submitted."

**Action**: For adoption

Request for Supplementary Information adopted on 19.05.2022.

### 5.1.19. Vemlidy - tenofovir alafenamide - EMEA/H/C/004169/II/0040

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Valentina Di Giovanni

Scope: "Extension of indication to include treatment of chronic hepatitis B-infected children from 6 years and older and weighing at least 25 kilograms for Vemlidy, based on the interim results from Week 24 clinical study report (CSR) for Cohort 1 and Cohort 2 Group 1 and supporting modular summaries for the category 3 study GS-US-320-1092, 'A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects with Chronic Hepatitis B Virus Infection'. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.
In addition, the MAH took the opportunity to update the wording in section 4.6 of the SmPC related to breastfeeding and pregnancies exposed to TAF, and to update the contact details of the local representative in Romania in the Package Leaflet. An updated RMP version 8.2 has been provided."

**Action**: For adoption

### 5.1.20. Wakix - pitolisant - Orphan - EMEA/H/C/002616/II/0030

Bioprojet Pharma

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension of indication to include treatment of narcolepsy with or without cataplexy in adolescents and children from the age of 6 years, based on results from study P11-06; an ongoing phase III, double-blind, multicentre, randomized, placebo-controlled trial undertaken to evaluate safety and efficacy of pitolisant in children from 6 to less than 18 years with narcolepsy with/without cataplexy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7.0 of the RMP has also been submitted."

**Action**: For adoption

### 5.1.21. Xalkori - crizotinib - EMEA/H/C/002489/II/0072

Pfizer Europe MA EEIG

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "Extension of indication to include treatment of paediatric patients (age ≥ 6 to < 18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumour (IMT) for Xalkori based on the results from studies ADVL0912 and A8081013; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH)

took the opportunity to update the ATC code for crizotinib. Moreover, the MAH took the opportunity to implement a minor change in the list of local representatives in the Package Leaflet."

**Action**: For adoption

Request for Supplementary Information adopted on 23.06.2022, 24.02.2022, 16.09.2021.

### 5.1.22. Yescarta - axicabtagene ciloleucel - Orphan - ATMP - EMEA/H/C/004480/II/0046

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Claire Beuneu, CHMP Coordinators: Jan Mueller-Berghaus and Karin Janssen van Doorn, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension of indication to include treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) for Yescarta; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.3 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the product information with minor editorial changes." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action**: For adoption

Request for Supplementary Information adopted on 15.07.2022, 13.05.2022, 18.02.2022.

## 5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

## 5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

# 6. Medical devices

## 6.1. Ancillary medicinal substances - initial consultation

No items

## 6.2. Ancillary medicinal substances – post-consultation update

No items

## 6.3. Companion diagnostics - initial consultation

### 6.3.1. in vitro diagnostic medical device - EMEA/H/D/006107

In vitro qualitative immunohistochemical detection of programmed death-ligand 1 (PD-L1)

Scope: Opinion

**Action:** For adoption

## 6.4. Companion diagnostics – follow-up consultation

No items

# 7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

## 7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

# 8. Pre-submission issues

## 8.1. Pre-submission issue

### 8.1.1. Respiratory Syncytial Virus - H0006054

indicated for active immunisation for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) in adults aged 60 years and older.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

**Action:** For adoption

## 8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

### 8.2.1. List of applications received

**Action:** For information

### 8.2.2. Recommendation for PRIME eligibility

**Action:** For adoption

# 9. Post-authorisation issues

## 9.1. Post-authorisation issues

### 9.1.1. Nulojix – belatacept – EMEA/H/C/002098

Bristol-Myers Squibb Pharma EEIG; prophylaxis of graft rejection in adults receiving a renal transplant

Rapporteur: Filip Josephson, Co-Rapporteur: Romaldas Mačiulaitis

Scope: DHPC and communication plan

**Action:** For adoption

### 9.1.2. Temybric Ellipta - fluticasone furoate/umeclidinium/vilanterol – EMEA/H/C/005254

GlaxoSmithKline Trading Services, treatment of asthma

Rapporteur: Jayne Crowe, Co-Rapporteur: Janet Koenig

Scope: Withdrawal of marketing authorisation

**Action:** For information

### 9.1.3. Qarziba - dinutuximab beta – Orphan - EMEA/H/C/003918/II/0043

EUSA Pharma (Netherlands) B.V.

Rapporteur: Paula Boudewina van Hennik

Scope: "Update of sections 4.1, 4.2 and 5.1 of the SmPC based on final results from study APN311-202V3 listed as a Specific Obligation in the Annex II of the Product Information. This is a Phase I/II dose schedule finding study of Ch14.18/CHO continuous infusion combined with subcutaneous aldesleukin (IL-2) in patients with primary refractory or relapsed neuroblastoma. In addition, the MAH took the opportunity to update Annex II section E. The Package Leaflet is updated accordingly."

**Action:** For adoption

### 9.1.4. Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0006

Pfizer Europe MA EEIG

Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Update of sections 4.5, 4.8 and 5.1 of the SmPC based on final results from study

B7471026 listed as a category 3 study in the RMP; this is a Phase III, randomized, double-blind trial to describe the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine when coadministered with a booster dose of BNT162b2 in adults 65 years of age and older; the Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted."

**Action:** For adoption

### 9.1.5. Rubraca - rucaparib - EMEA/H/C/004272/II/0029

Clovis Oncology Ireland Limited

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin

Scope: "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on final results from study CO-338-043 (ARIEL4); this is a phase 3, multicentre, open-label, randomised study evaluating the efficacy and safety of rucaparib versus chemotherapy for treatment of relapsed ovarian cancer listed as a specific obligation in the Annex II; the Package Leaflet is updated accordingly. The RMP version 6.1 has also been submitted. With this variation application, the MAH requests for the Rubraca marketing authorisation to no longer be subject to specific obligations. The SmPC, Annex II and PL are updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes and bring the PI in line with the latest QRD template version 10.2 Rev.1."

**Action:** For adoption

Request for Supplementary Information adopted on 21.07.2022, 24.03.2022, 11.11.2021.

### 9.1.6. Spikevax - elasomeran - EMEA/H/C/005791/II/0075/G

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Addition of a new strain (Omicron BA.1) resulting in two new Spikevax bivalent Original/Omicron (25 µg elasomeran / 25 µg imelasomeran per dose) 0.1 mg/mL dispersion for injection presentations. The SmPC, the Package Leaflet and Labelling are updated accordingly. The submission includes a revised RMP version 4.2.

Positive opinion adopted by consensus at the extraordinary meeting held on 01.09.2022.

**Action**: For information

### 9.1.7. Comirnaty - tozinameran - EMEA/H/C/005735/II/0140

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst

Scope: Addition of a new strain (Omicron BA.1) resulting in a new Comirnaty bivalent Original/Omicron BA.1 (15 µg tozinameran/ 15 µg riltozinameran per dose) dispersion for injection presentation. The SmPC, the Package Leaflet and Labelling are updated accordingly. The submission includes a revised RMP version 6.0.

Positive opinion adopted by consensus at the extraordinary meeting held on 01.09.2022.

**Action**: For information

### 9.1.8. Nuvaxovid - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0014

Novavax CZ, a.s.

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to include a 0.5 mL third dose for Nuvaxovid, to boost subjects that have previously completed a primary vaccination series with Nuvaxovid (homologous booster dose) or with an authorised mRNA or adenoviral vector vaccine (heterologous booster dose), based on interim data from study 2019nCoV-101 (Part 2), a Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With or Without Matrix-M Adjuvant in Healthy Subjects (NCT04368988), final data from study 2019nCoV-501, a Phase 2a/b, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV (NCT04533399) and data from the COV-BOOST study (Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial); the Package Leaflet is updated accordingly. The RMP version 1.2 has also been submitted. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to make minor editorial corrections throughout the product information."

Positive opinion adopted by consensus at the extraordinary meeting held on 01.09.2022.

**Action:** For information

### 9.1.9. Comirnaty - tozinameran - EMEA/H/C/005735/II/0143

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst

Scope: "Addition of a new strain (Omicron BA.4-5) resulting in a new Comirnaty bivalent Original/Omicron BA.4-5 (15 µg / 15 µg per dose) dispersion for injection presentation. The SmPC, the Package Leaflet and Labelling are updated accordingly. The submission includes a revised RMP version 7.0."

**Action:** For adoption

### 9.1.10. Comirnaty - tozinameran - EMEA/H/C/005735/R/0137

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst

Scope: Renewal of conditional marketing authorisation

**Action:** For adoption

### 9.1.11. Spikevax - elasomeran - EMEA/H/C/005791/R/0074

Moderna Biotech Spain, S.L.,

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Renewal of conditional marketing authorisation

**Action:** For adoption

### 9.1.12. Caprelsa - vandetanib - EMEA/H/C/002315/R/0055

Genzyme Europe BV

Rapporteur: Alexandre Moreau, Co-Rapporteur: Paula Boudewina van Hennik

Scope: Renewal of marketing authorisation

**Action:** For adoption

### 9.1.13. Caprelsa - vandetanib - EMEA/H/C/002315/II/0043

Genzyme Europe BV

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "C.I.4 Update of section 5.1 of the SmPC in order to update pharmacodynamic information based on interim results from study D4200C00104, listed as a specific obligation in the Annex II. This is an observational study (including a retrospective arm to evaluate the Benefit/Risk of vandetanib (Caprelsa) 300 mg in RET mutation negative and RET mutation positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic thyroid cancer (MTC)), to confirm the efficacy and safety of Caprelsa in RET-negative patients with the aim to fulfil SOB001 and convert Caprelsa from conditional to normal Marketing Authorisation.
In addition, the MAH takes to opportunity to rectify the Dutch translation of the Caprelsa Product Information."

**Action:** For adoption

Request for Supplementary Information adopted on 19.05.2022, 16.12.2021, 24.06.2021, 28.05.2020.

### 9.1.14. Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0056

Orexigen Therapeutics Ireland Limited

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber

Scope: "Submission of updated study design and protocol synopsis for CVOT-2 study, a category 1 study listed in Annex II.D (ANX/001.7) undertaken to assess the effect of naltrexone extended release (ER) / bupropion ER on the occurrence of major adverse cardiovascular events (MACE), as requested in the CHMP AR for ANX/001.6. The Annex II and the RMP version 13 are updated accordingly."

**Action:** For adoption

Request for Supplementary Information adopted on 24.03.2022.

### 9.1.15. NeoRecormon – epoetin beta – EMEA/H/C/000116

Roche Registration GmbH

Rapporteur: Martina Weise, Co-Rapporteur : Alexandre Moreau

Scope: DHPC

**Action:** For adoption

# 10. Referral procedures

## 10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

## 10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

## 10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

## 10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

### 10.4.1. Rambis - EMEA/H/A-29(4)/1519

Adamed Pharma S.A.

Rapporteur: Ewa Balkowiec Iskra, Co-Rapporteur: Ondrej Slanar

Scope: List of outstanding issues

**Action:** For adoption

Decentralised procedure number: PL/H/0758/001-006/DC, notification by the Agency of Poland dated 30 May 2022 notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC

## 10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

## 10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

### 10.6.1. Chlormadinone (NAP); chlormadinone, ethinylestradiol (NAP); nomegestrol (NAP); nomegestrol, estradiol – ZOELY (CAP); NAP - EMEA/H/A-31/1510

Applicant(s): Theramex Ireland Limited (Zoely), various

PRAC Rapporteur: Martin Huber; PRAC Co-rapporteur: Zeljana Margan Koletic

Review of the benefit-risk balance following notification by France of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data

Scope: Opinion

The CHMP adopted a positive opinion by majority (26 out of 28 votes) at the extraordinary meeting held on 01.09.2022

The divergent position (Jean-Michel Race and Alexandra Branchu) was appended to the opinion.

**Action:** For information

## 10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

### 10.7.1. Synchron Research Services – various – EMEA/H/A-31/1515

Various MAHs

Re-examination Referral Rapporteur: John Joseph Borg, Referral Co-Rapporteur: Paula Boudewina van Hennik

Scope: Opinion

**Action:** For adoption

## 10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

## 10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

## 10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

## 10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

# 11. Pharmacovigilance issue

## 11.1. Early Notification System

September 2022 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

**Action**: For information

# 12. Inspections

## 12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

## 12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

## 12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

## 12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

# 13. Innovation Task Force

## 13.1. Minutes of Innovation Task Force

No items

## 13.2. Innovation Task Force briefing meetings

No items

## 13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

## 13.4. Nanomedicines activities

No items

# 14. Organisational, regulatory and methodological matters

## 14.1. Mandate and organisation of the CHMP

### 14.1.1. CHMP membership

None

### 14.1.2. Vote by proxy

None

## 14.2. Coordination with EMA Scientific Committees

### 14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for September 2022

**Action:** For adoption

### 14.2.2. Paediatric Committee (PDCO)

PIPs reaching D30 at September 2022 PDCO

**Action:** For information

Report from the PDCO meeting held on 06-09 September 2022

**Action:** For information

## 14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

### 14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/Nanna Aaby Kruse

Reports from BWP September 2022 meeting to CHMP for adoption:

- 12 reports on products in scientific advice and protocol assistance
- 11 reports on products in pre-authorisation procedures
- 1 report on products in post-authorisation procedures
- 3 reports on products in plasma master file

**Action:** For adoption

### 14.3.2. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 29 August - 01 September 2022. Table of conclusions

**Action:** For information

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

### 14.3.3. EC Request for a scientific opinion on the classification as medicinal products of certain substances used in blood bags CDP (citrate, dextrose and phosphate) and CDPA (citrate, dextrose, phosphate and adenine)

Discussion and endorsement of a response letter to the EC.

**Action:** For adoption

### 14.3.4. Call for expression of interest for EMA/EC expert to the ICH E11A (paediatric extrapolation) expert working group

A call for expression of interest for the appointment of a new expert to represent CHMP/EMA/EC in the ICH E11A working group, working on an ongoing guideline on paediatric extrapolation, was launched with the Modelling and Simulation WP with a deadline of 25 August. Following endorsement from MWP chair and vice-chair, an expert nomination is now brought to CHMP for endorsement:

**Action:** For endorsement

## 14.4. Cooperation within the EU regulatory network

No items

## 14.5. Cooperation with International Regulators

No items

## 14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

## 14.7. CHMP work plan

No items

## 14.8. Planning and reporting

### 14.8.1. Update of the Business Pipeline report for the human scientific committees

Q3-2022 initial marketing authorisation application submissions with eligibility request to central procedure

**Action:** For information

## 14.9. Others

No items

# 15. Any other business

## 15.1. AOB topic

### 15.1.1. Update on COVID-19

**Action:** For information

# Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

**Oral explanations** *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

**Initial applications** *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:




The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

**Extension of marketing authorisations according to Annex I of Reg. 1234/2008** *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

**Type II variations - Extension of indication procedures** *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

**Ancillary medicinal substances in medical devices** *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

**Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004** *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

**Re-examination procedures** *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

**Withdrawal of application** *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

**Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use)** *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

**Pre-submission issues** *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

**Post-authorisation issues** *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

**Referral procedures** *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

**Pharmacovigilance issues** *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

**Inspections Issues** *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

**Innovation task force** *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

**Scientific advice working party (SAWP)** *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

**Satellite groups / other committees** *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

**Invented name issues** *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

12 September 2022
EMA/CHMP/700568/2022

# Annex to 12-15 September 2022 CHMP Agenda

Pre-submission and post-authorisations issues




**Official address** Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
**Address for visits and deliveries** Refer to www.ema.europa.eu/how-to-find-us
**Send us a question** Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

## A. PRE-SUBMISSION ISSUES

### A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for September 2022: **For adoption**

### A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Outcome of Rapporteurship allocation for September 2022: **For adoption**

### A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

## B. POST-AUTHORISATION PROCEDURES OUTCOMES

### B.1. Annual re-assessment outcomes

#### B.1.1. Annual reassessment for products authorised under exceptional circumstances

**Elaprase - idursulfase - EMEA/H/C/000700/S/0099**
Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan
Request for Supplementary Information adopted on 21.07.2022.

**EVKEEZA - evinacumab - EMEA/H/C/005449/S/0005**
Ultragenyx Germany GmbH, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Mari Thorn

### B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

#### B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

**Anagrelide Mylan - anagrelide - EMEA/H/C/004585/R/0010**
Mylan Pharmaceuticals Limited, Generic,

Generic of Xagrid, Rapporteur: Alar Irs, PRAC Rapporteur: Tiphaine Vaillant

### B.2.2. Renewals of Marketing Authorisations for unlimited validity

**ADYNOVI - rurioctocog alfa pegol - EMEA/H/C/004195/R/0033**
Baxalta Innovations GmbH, Rapporteur: Andrea Laslop, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst
Request for Supplementary Information adopted on 21.07.2022.

**Alkindi - hydrocortisone - EMEA/H/C/004416/R/0014**
Diurnal Europe BV, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Mari Thorn
Request for Supplementary Information adopted on 21.07.2022.

**Alofisel - darvadstrocel - EMEA/H/C/004258/R/0036, Orphan, ATMP**
Takeda Pharma A/S, Rapporteur: Lisbeth Barkholt, Co-Rapporteur: Margarida Menezes-Ferreira, CHMP Coordinators: Kristina Dunder and Fátima Ventura, PRAC Rapporteur: Brigitte Keller-Stanislawski

**Darunavir Krka - darunavir - EMEA/H/C/004273/R/0013**
KRKA, d.d., Novo mesto, Generic, Generic of Prezista, Rapporteur: John Joseph Borg, PRAC Rapporteur: Liana Gross-Martirosyan

**Efavirenz/Emtricitabine/Tenofovir disoproxil Krka - efavirenz / emtricitabine / tenofovir disoproxil - EMEA/H/C/004274/R/0015**
KRKA, d.d., Novo mesto, Generic, Generic of Atripla (SRD), Rapporteur: John Joseph Borg, PRAC Rapporteur: Martin Huber

**Fulvestrant Mylan - fulvestrant - EMEA/H/C/004649/R/0016**
Mylan Pharmaceuticals Limited, Generic, Generic of Faslodex, Rapporteur: Elita Poplavska, PRAC Rapporteur: Ulla Wändel Liminga

**Herzuma - trastuzumab - EMEA/H/C/002575/R/0050**
Celltrion Healthcare Hungary Kft., Rapporteur:

| | |
|---|---|
| Jan Mueller-Berghaus, Co-Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Brigitte Keller-Stanislawski | |
| **Mylotarg - gemtuzumab ozogamicin - EMEA/H/C/004204/R/0025, Orphan**<br>Pfizer Europe MA EEIG, Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva | |
| **Segluromet - ertugliflozin / metformin hydrochloride - EMEA/H/C/004314/R/0015**<br>Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Menno van der Elst | |
| **Steglatro - ertugliflozin - EMEA/H/C/004315/R/0015**<br>Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Menno van der Elst | |
| **Steglujan - ertugliflozin / sitagliptin - EMEA/H/C/004313/R/0018**<br>Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Menno van der Elst | |

### B.2.3. Renewals of Conditional Marketing Authorisations

| | |
|---|---|
| **Caprelsa - vandetanib - EMEA/H/C/002315/R/0055**<br>Genzyme Europe BV, Rapporteur: Alexandre Moreau, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Tiphaine Vaillant | |
| **COMIRNATY - tozinameran - EMEA/H/C/005735/R/0137**<br>BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst | See 9.1 |
| **Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/R/0023**<br>Daiichi Sankyo Europe GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Marcia | |

| | |
|---|---|
| Sofia Sanches de Castro Lopes Silva | |
| **Lumykras - sotorasib - EMEA/H/C/005522/R/0002**<br>Amgen Europe B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Marie Louise Schougaard Christiansen | |
| **NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/R/0020**<br>Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski | |
| **Ocaliva - obeticholic acid - EMEA/H/C/004093/R/0034, Orphan**<br>Intercept Pharma International Limited, Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan | |
| **Spikevax - elasomeran - EMEA/H/C/005791/R/0074**<br>Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen | See 9.1 |
| **Tecartus - brexucabtagene autoleucel - EMEA/H/C/005102/R/0025, Orphan, ATMP**<br>Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Rune Kjeken, PRAC Rapporteur: Menno van der Elst | |

## B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

**Post-authorisation safety studies**

PRAC recommendations on PASS results adopted at the PRAC meeting held on 29 August – 01 September 2022

**XARELTO (CAP) -**
**EMEA/H/C/PSR/S/0027**
(rivaroxaban)
CHMP Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga
Scope: Assessment of final study report comprising the pharmacoepidemiological imposed study program of rivaroxaban use and potential adverse outcomes in routine clinical practice in the UK, Germany, the Netherlands and Sweden.
PRAC recommendation to CHMP
**Action:** For adoption

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its September 2022 meeting:

**EMEA/H/C/PSUSA/00002645/202112**
(riluzole)
CAPS:
**Rilutek** (EMEA/H/C/000109) (riluzole), Sanofi Mature IP, Rapporteur: Thalia Marie Estrup Blicher
**Riluzole Zentiva** (EMEA/H/C/002622) (riluzole), Zentiva, k.s., Rapporteur: Thalia Marie Estrup Blicher
NAPS:
**EU** - NAPs
PRAC Rapporteur: Anette Kirstine Stark, "12/12/2019 To: 12/12/2021"

**EMEA/H/C/PSUSA/00003085/202112**
(ustekinumab)
CAPS:
**Stelara** (EMEA/H/C/000958) (ustekinumab), Janssen-Cilag International N.V., Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald, "01/01/2021 To: 31/12/2021"

**EMEA/H/C/PSUSA/00010263/202112**
(umeclidinium)
CAPS:
**Incruse Ellipta** (EMEA/H/C/002809) (umeclidinium bromide), GlaxoSmithKline (Ireland) Limited, Rapporteur: Maria Concepcion Prieto Yerro
**Rolufta Ellipta** (EMEA/H/C/004654) (umeclidinium), GlaxoSmithKline Trading Services Limited, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Amelia Cupelli, "18/12/2018 To: 17/12/2021"

| |
|---|
| **EMEA/H/C/PSUSA/00010264/202112**<br>(umeclidinium bromide / vilanterol)<br>CAPS:<br>**Anoro Ellipta** (EMEA/H/C/002751) (umeclidinium / vilanterol), GlaxoSmithKline (Ireland) Limited, Rapporteur: Jayne Crowe<br>**Laventair Ellipta** (EMEA/H/C/003754) (umeclidinium / vilanterol), GlaxoSmithKline (Ireland) Limited, Rapporteur: Jayne Crowe, PRAC Rapporteur: Amelia Cupelli, "18/12/2018 To: 17/12/2021" |
| **EMEA/H/C/PSUSA/00010695/202202**<br>(bictegravir / emtricitabine / tenofovir alafenamide)<br>CAPS:<br>**Biktarvy** (EMEA/H/C/004449) (bictegravir / emtricitabine / tenofovir alafenamide), Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Liana Gross-Martirosyan, "07/08/2021 To: 06/02/2022" |
| **EMEA/H/C/PSUSA/00010820/202201**<br>(osilodrostat)<br>CAPS:<br>**Isturisa** (EMEA/H/C/004821) (osilodrostat), Recordati Rare Diseases, Rapporteur: Kristina Dunder, PRAC Rapporteur: Eva A. Segovia, "08/01/2021 To: 08/01/2022" |
| **EMEA/H/C/PSUSA/00010924/202201**<br>(remimazolam)<br>CAPS:<br>**Byfavo** (EMEA/H/C/005246) (remimazolam), PAION Netherlands B.V., Rapporteur: Bruno Sepodes, PRAC Rapporteur: Rhea Fitzgerald, "22/07/2021 To: 22/01/2022" |

### B.4. EPARs / WPARs

### B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

#### B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

| | |
|---|---|
| **ADCETRIS - brentuximab vedotin - EMEA/H/C/002455/II/0102/G, Orphan**<br>Takeda Pharma A/S, Rapporteur: Paula | Positive Opinion adopted by consensus on 01.09.2022. |

| | |
|---|---|
| Boudewina van Hennik<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 23.06.2022. | |
| **Adtralza - tralokinumab - EMEA/H/C/005255/II/0005**<br>LEO Pharma A/S, Rapporteur: Jayne Crowe<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **Alecensa - alectinib - EMEA/H/C/004164/II/0041**<br>Roche Registration GmbH, Rapporteur: Filip Josephson<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0007/G**<br>Pfizer Europe MA EEIG, Rapporteur: Daniela Philadelphy | |
| **Aranesp - darbepoetin alfa - EMEA/H/C/000332/II/0161**<br>Amgen Europe B.V., Rapporteur: Martina Weise | |
| **ARIKAYCE liposomal - amikacin - EMEA/H/C/005264/II/0008/G, Orphan**<br>Insmed Netherlands B.V., Rapporteur: Jayne Crowe | |
| **BLINCYTO - blinatumomab - EMEA/H/C/003731/II/0047/G, Orphan**<br>Amgen Europe B.V., Rapporteur: Alexandre Moreau<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 16.06.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Elaprase - idursulfase - EMEA/H/C/000700/II/0101**<br>Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Johann Lodewijk Hillege<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Erbitux - cetuximab - EMEA/H/C/000558/II/0094/G**<br>Merck Europe B.V., Rapporteur: Filip Josephson<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **EVUSHELD - tixagevimab / cilgavimab - EMEA/H/C/005788/II/0002/G** | |

| | |
|---|---|
| AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus<br>Request for Supplementary Information adopted on 21.07.2022. | |
| **Fortacin - lidocaine / prilocaine - EMEA/H/C/002693/II/0035/G**<br>Recordati Ireland Ltd, Rapporteur: Maria Concepcion Prieto Yerro | |
| **Gazyvaro - obinutuzumab - EMEA/H/C/002799/II/0050, Orphan**<br>Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Grepid - clopidogrel - EMEA/H/C/001059/II/0054**<br>Pharmathen S.A., Generic, Generic of Plavix, Rapporteur: Nevenka Trsinar Brodt | |
| **Hepcludex - bulevirtide - EMEA/H/C/004854/II/0014/G, Orphan**<br>Gilead Sciences Ireland Unlimited Company, Rapporteur: Filip Josephson<br>Request for Supplementary Information adopted on 23.06.2022. | |
| **Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0135**<br>CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus<br>Request for Supplementary Information adopted on 02.06.2022. | |
| **Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0136/G**<br>CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 16.06.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0139**<br>CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **Increlex - mecasermin - EMEA/H/C/000704/II/0077/G**<br>Ipsen Pharma, Rapporteur: Outi Mäki-Ikola<br>Request for Supplementary Information adopted | |

| | |
|---|---|
| on 21.07.2022. | |
| **JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0057**<br>Janssen-Cilag International N.V., Rapporteur: Christophe Focke<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0058/G**<br>Janssen-Cilag International N.V., Rapporteur: Christophe Focke<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Jivi - damoctocog alfa pegol - EMEA/H/C/004054/II/0024/G**<br>Bayer AG, Rapporteur: Thalia Marie Estrup Blicher | |
| **Kadcyla - trastuzumab emtansine - EMEA/H/C/002389/II/0066/G**<br>Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher<br>Request for Supplementary Information adopted on 21.07.2022. | |
| **Kovaltry - octocog alfa - EMEA/H/C/003825/II/0039**<br>Bayer AG, Rapporteur: Kristina Dunder<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **LIVOGIVA - teriparatide - EMEA/H/C/005087/II/0010**<br>Theramex Ireland Limited, Rapporteur: Daniela Philadelphy<br>Request for Supplementary Information adopted on 23.06.2022. | |
| **Lyumjev - insulin lispro - EMEA/H/C/005037/II/0016**<br>Eli Lilly Nederland B.V., Rapporteur: Outi Mäki-Ikola | |
| **NovoSeven - eptacog alfa (activated) - EMEA/H/C/000074/II/0117**<br>Novo Nordisk A/S, Rapporteur: Paula Boudewina van Hennik<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 16.06.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Nuceiva - botulinum toxin type A - EMEA/H/C/004587/II/0027** | Request for supplementary information adopted with a specific timetable. |

| | |
|---|---|
| Evolus Pharma B.V., Rapporteur: Jayne Crowe<br>Request for Supplementary Information adopted on 01.09.2022. | |
| **Obizur - susoctocog alfa - EMEA/H/C/002792/II/0047/G**<br>Baxalta Innovations GmbH, Rapporteur: Andrea Laslop<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **Ocaliva - obeticholic acid - EMEA/H/C/004093/II/0035, Orphan**<br>Intercept Pharma International Limited, Rapporteur: Blanca Garcia-Ochoa | |
| **Ogluo - glucagon - EMEA/H/C/005391/II/0005/G**<br>Tetris Pharma B.V., Rapporteur: Karin Janssen van Doorn | |
| **Onpattro - patisiran - EMEA/H/C/004699/II/0027/G, Orphan**<br>Alnylam Netherlands B.V., Rapporteur: Kristina Dunder<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Phesgo - pertuzumab / trastuzumab - EMEA/H/C/005386/II/0012/G**<br>Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **Polivy - polatuzumab vedotin - EMEA/H/C/004870/II/0017/G, Orphan**<br>Roche Registration GmbH, Rapporteur: Alexandre Moreau<br>Request for Supplementary Information adopted on 21.07.2022, 23.06.2022. | |
| **Prasugrel Mylan - prasugrel - EMEA/H/C/004644/II/0013**<br>Mylan Pharmaceuticals Limited, Generic, Generic of Efient, Rapporteur: Alar Irs | |
| **Prevenar 13 - pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) - EMEA/H/C/001104/II/0206/G**<br>Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **PREVYMIS - letermovir -** | Request for supplementary information adopted |

| | |
|---|---|
| **EMEA/H/C/004536/II/0028/G, Orphan**<br>Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson<br>Request for Supplementary Information adopted on 01.09.2022. | with a specific timetable. |
| **Privigen - human normal immunoglobulin - EMEA/H/C/000831/II/0188**<br>CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus<br>Request for Supplementary Information adopted on 14.07.2022. | |
| **Puregon - follitropin beta - EMEA/H/C/000086/II/0124**<br>Organon N.V., Rapporteur: Jayne Crowe<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 07.07.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Qarziba - dinutuximab beta - EMEA/H/C/003918/II/0045, Orphan**<br>EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Rekovelle - follitropin delta - EMEA/H/C/003994/II/0034**<br>Ferring Pharmaceuticals A/S, Rapporteur: Jean-Michel Race<br>Request for Supplementary Information adopted on 01.09.2022, 21.07.2022. | Request for supplementary information adopted with a specific timetable. |
| **Respreeza - human alpha1-proteinase inhibitor - EMEA/H/C/002739/II/0060**<br>CSL Behring GmbH, Rapporteur: Kristina Dunder<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **RINVOQ - upadacitinib - EMEA/H/C/004760/II/0025/G**<br>AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder | |
| **Ruxience - rituximab - EMEA/H/C/004696/II/0011**<br>Pfizer Europe MA EEIG, Rapporteur: Paula Boudewina van Hennik<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 16.06.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Sialanar - glycopyrronium - EMEA/H/C/003883/II/0025/G** | Positive Opinion adopted by consensus on 01.09.2022. |

| | |
|---|---|
| Proveca Pharma Limited, Rapporteur: Thalia Marie Estrup Blicher<br>Opinion adopted on 01.09.2022. | |
| **Simulect - basiliximab - EMEA/H/C/000207/II/0114/G**<br>Novartis Europharm Limited, Rapporteur: Jan Mueller-Berghaus<br>Request for Supplementary Information adopted on 23.06.2022. | |
| **Spectrila - asparaginase - EMEA/H/C/002661/II/0029**<br>medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Andrea Laslop<br>Request for Supplementary Information adopted on 01.09.2022, 02.06.2022. | Request for supplementary information adopted with a specific timetable. |
| **Spectrila - asparaginase - EMEA/H/C/002661/II/0031**<br>medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Andrea Laslop<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 07.07.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Stelara - ustekinumab - EMEA/H/C/000958/II/0094/G**<br>Janssen-Cilag International N.V., Rapporteur: Jayne Crowe<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 14.07.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Tecentriq - atezolizumab - EMEA/H/C/004143/II/0070/G**<br>Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Tysabri - natalizumab - EMEA/H/C/000603/II/0133**<br>Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus<br>Request for Supplementary Information adopted on 08.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **Ultomiris - ravulizumab - EMEA/H/C/004954/II/0029**<br>Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa | Positive Opinion adopted by consensus on 01.09.2022. |

| | |
|---|---|
| Opinion adopted on 01.09.2022. | |
| **Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0104/G**<br>MCM Vaccine B.V., Rapporteur: Christophe Focke | |
| **Vaxneuvance - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/005477/II/0007/G**<br>Merck Sharp & Dohme B.V., Rapporteur: Johann Lodewijk Hillege<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0076/G**<br>AstraZeneca AB, Rapporteur: Sol Ruiz<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Vazkepa - icosapent ethyl - EMEA/H/C/005398/II/0009/G**<br>Amarin Pharmaceuticals Ireland Limited, Rapporteur: Martina Weise<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **Vectibix - panitumumab - EMEA/H/C/000741/II/0099**<br>Amgen Europe B.V., Rapporteur: Eva Skovlund<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Votrient - pazopanib - EMEA/H/C/001141/II/0071/G**<br>Novartis Europharm Limited, Rapporteur: Aaron Sosa Mejia<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 02.06.2022, 17.02.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **VPRIV - velaglucerase alfa - EMEA/H/C/001249/II/0055, Orphan**<br>Takeda Pharmaceuticals International AG, Rapporteur: Martina Weise<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 21.07.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Xenical - orlistat - EMEA/H/C/000154/II/0086** | |

| | |
|---|---|
| CHEPLAPHARM Arzneimittel GmbH, Rapporteur: Jean-Michel Race | |
| **WS2138/G**<br>**Hexacima-**<br>**EMEA/H/C/002702/WS2138/0120/G**<br>**Hexyon-**<br>**EMEA/H/C/002796/WS2138/0124/G**<br>Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 23.06.2022, 22.04.2022, 02.12.2021. | Positive Opinion adopted by consensus on 01.09.2022. |
| **WS2283/G**<br>**Eucreas-**<br>**EMEA/H/C/000807/WS2283/0098/G**<br>**Galvus-**<br>**EMEA/H/C/000771/WS2283/0077/G**<br>**Icandra-**<br>**EMEA/H/C/001050/WS2283/0103/G**<br>**Jalra-**<br>**EMEA/H/C/001048/WS2283/0080/G**<br>**Xiliarx-**<br>**EMEA/H/C/001051/WS2283/0078/G**<br>**Zomarist-**<br>**EMEA/H/C/001049/WS2283/0100/G**<br>Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **WS2288**<br>**Humalog-**<br>**EMEA/H/C/000088/WS2288/0196**<br>**Liprolog-**<br>**EMEA/H/C/000393/WS2288/0156**<br>Eli Lilly Nederland B.V., Lead Rapporteur: Kristina Dunder<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **WS2296/G**<br>**Infanrix hexa-**<br>**EMEA/H/C/000296/WS2296/0316/G**<br>GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke | |
| **WS2300/G**<br>**Infanrix hexa-**<br>**EMEA/H/C/000296/WS2300/0317/G**<br>GlaxoSmithkline Biologicals SA, Lead | |

| | |
|---|---|
| Rapporteur: Christophe Focke | |
| **WS2313**<br>**Hexacima-**<br>**EMEA/H/C/002702/WS2313/0133**<br>**Hexyon-**<br>**EMEA/H/C/002796/WS2313/0137**<br>Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus | |
| **WS2319**<br>**Nuwiq-EMEA/H/C/002813/WS2319/0049**<br>**Vihuma-**<br>**EMEA/H/C/004459/WS2319/0031**<br>Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **WS2327**<br>**Incresync-**<br>**EMEA/H/C/002178/WS2327/0042**<br>**Vipdomet-**<br>**EMEA/H/C/002654/WS2327/0039**<br>**Vipidia-EMEA/H/C/002182/WS2327/0031**<br>Takeda Pharma A/S, Lead Rapporteur: Johann Lodewijk Hillege | |

### B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

| | |
|---|---|
| **Adakveo - crizanlizumab -**<br>**EMEA/H/C/004874/II/0007, Orphan**<br>Novartis Europharm Limited, Rapporteur: Daniela Philadelphy, "Update of section 5.2 of the SmPC in order to update pharmacokinetic information based on the results from PK reanalysis. In addition, the MAH took the opportunity to introduce minor editorial changes to the SmPC."<br>Request for Supplementary Information adopted on 12.05.2022. | |
| **Avonex - interferon beta-1A -**<br>**EMEA/H/C/000102/II/0192**<br>Biogen Netherlands B.V., Rapporteur: Maria Concepcion Prieto Yerro, "Update of section 4.4 of the SmPC in order to add a new warning regarding the risk of injection site necrosis based on post marketing experience. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the | Positive Opinion adopted by consensus on 01.09.2022. |

| | |
|---|---|
| Package Leaflet."<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 12.05.2022. | |
| **Bavencio - avelumab - EMEA/H/C/004338/II/0035**<br>Merck Europe B.V., Rapporteur: Filip Josephson, "Update of sections 4.2, 5.1 and 5.2 of the SmPC based on final results from study MS100070-0306 following a P46 procedure (EMEA/H/C/004338/P46/009). This is a Phase I, multi-centre, open-label, international study to evaluate the dose, safety and tolerability, antitumor activity, pharmacokinetic and pharmacodynamics of avelumab in paediatric subjects 0 to less than 18 years of age with refractory or relapsed malignant solid tumours (including central nervous system tumours) and lymphoma for which no standard therapy is available or for which the subject is not eligible for the existing therapy. In addition, the MAH took the opportunity to update Annex II section D to be aligned with the EU Educational materials (EM) and the EU Risk Management Plan (RMP).<br>Furthermore, the MAH took the opportunity to implement editorial changes." | |
| **Besremi - ropeginterferon alfa-2b - EMEA/H/C/004128/II/0021**<br>AOP Orphan Pharmaceuticals GmbH, Rapporteur: Janet Koenig, "Update of sections 4.8, 5.1 and 5.2 of the SmPC based on results from CONTINUATION-PV study. An open-label, multicentre, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with polycythaemia vera who previously participated in the PROUDPV study. The Package Leaflet is updated accordingly."<br>Request for Supplementary Information adopted on 01.09.2022, 23.06.2022. | Request for supplementary information adopted with a specific timetable. |
| **Bexsero - meningococcal group B vaccine (recombinant, component, adsorbed) - EMEA/H/C/002333/II/0112**<br>GSK Vaccines S.r.l, Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to add information based on Real World Evidence (RWE) on vaccination impact and effectiveness from literature references available up to July | |

2021. The MAH also proposes to remove the existing statement related to paediatric studies in section 5.1 of the SmPC. In addition, the MAH took the opportunity to introduce minor editorial changes to the SmPC."
Request for Supplementary Information adopted on 02.06.2022.

**CABOMETYX - cabozantinib - EMEA/H/C/004163/II/0029**
Ipsen Pharma, Rapporteur: Ingrid Wang, "Update of sections 4.4 and 4.8 of the SmPC in order to update special warnings data and information of adverse drug reactions (ADRs) based on results from study XL184-311 (COSMIC-311); study XL184-311 was a Phase 3 international, multicenter, randomized, double-blind, placebo-controlled study of cabozantinib in subjects with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who had progressed during or after prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy.
In addition, the MAH is taking this opportunity to propose minor updates to the Package Leaflet."

**Calquence - acalabrutinib - EMEA/H/C/005299/II/0013**
AstraZeneca AB, Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to update efficacy and safety information based on final results from study ACE-CL-309 (A Phase 3 randomized open-label active-control study investigating Calquence for the Treatment of Subjects With Relapsed or Refractory Chronic Lymphocytic Leukaemia) listed as a category 3 study in the RMP."

**Cervarix - human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) - EMEA/H/C/000721/II/0115**
GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, "Submission of the final report from study HPV-027 listed as a category 3 study in the RMP to fulfil MEA 024.2; this is a long-term follow-up registry-based cohort study of HPV vaccine effectiveness against cervical pre-cancerous lesions and cervical cancer in a cohort of females previously enrolled from Finland in study HPV-008, as compared to an unvaccinated population-based reference cohort

of females from Finland."

**Cibinqo - abrocitinib - EMEA/H/C/005452/II/0005**

Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder, "Update of section 4.5 of the SmPC based on final results from Drug-Drug Interaction (DDI) study B7451092. This is a Phase I, open-label, fixed-sequence, 2-period study to estimate the effect of multiple dose abrocitinib on the pharmacokinetics of single doses of caffeine, efavirenz, and omeprazole in healthy participants."

**COMIRNATY - tozinameran - EMEA/H/C/005735/II/0129**

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Update of sections 4.2, 4.8 and 5.1 of the SmPC of COMIRNATY 10 µg Concentrate for dispersion for injection in order to introduce a booster dose for children 5 to 11 years of age based on interim results from study C4591007 listed as a specific obligation in the Annex II; this is a Phase 1, Open-Label Dose-Finding Study to Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo-Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of a SARS-CoV-2 RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults; the Package Leaflet is updated accordingly.
In addition, the MAH took the opportunity to make minor editorial changes throughout the product information."
Request for Supplementary Information adopted on 23.06.2022.

**Darzalex - daratumumab - EMEA/H/C/004077/II/0062, Orphan**

Janssen-Cilag International N.V., Rapporteur: Aaron Sosa Mejia, "Update of section 4.8 of the SmPC in order to add COVID-19 to the list of adverse drug reactions (ADRs) with frequency uncommon, based on a pooled dataset from the following interventional studies 4767414MMY2004, 54767414MMY3003, 54767414MMY3006, 54767414MMY3008, and 54767414MMY3013. The Package Leaflet is updated accordingly."

**Evoltra - clofarabine -**

| | |
|---|---|
| **EMEA/H/C/000613/II/0077**<br>Genzyme Europe BV, Rapporteur: Alexandre Moreau, "Update of the Package Leaflet in order to update information regarding breast-feeding based on a comprehensive safety review. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." | |
| **JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0060**<br>Janssen-Cilag International N.V., Rapporteur: Christophe Focke, "Update of section 4.8 of the SmPC in order to update the list of adverse drug reactions (ADRs) based on pooled analyses of clinical safety data from the following Phase III interventional studies: VAC31518COV3001 and VAC31518COV3009; and from the Phase I/II interventional studies: VAC31518COV1001, VAC31518COV1002, VAC31518COV1003 and VAC31518COV2001. The Package Leaflet is updated accordingly." | |
| **Keytruda - pembrolizumab - EMEA/H/C/003820/II/0126**<br>Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, "To update sections 4.2 and 5.2 of the SmPC to include data for patients with moderate hepatic impairment based on KEYNOTE-240 (a double-blind, randomized, Phase 3 study of pembrolizumab in participants with previously systemically treated advanced HCC) and KEYNOTE-224 (a Phase 2 study of pembrolizumab as monotherapy in participants with advanced HCC).<br>The MAH took the opportunity to make some editorial changes." | |
| **Leqvio - inclisiran - EMEA/H/C/005333/II/0011**<br>Novartis Europharm Limited, Rapporteur: Martina Weise, "Submission of the final report from non-clinical study no. 2120284 in order to address a recommendation (REC). This is an in-silico assessment of the cross-tissue mRNA expression of the genes encoding for SULF1, INSYN2B (also referred to as FAM196B), ASGR1 and ASGR2 in tissues in man, monkey, rat and mouse."<br>Request for Supplementary Information adopted | Request for supplementary information adopted with a specific timetable. |

| | |
|---|---|
| on 01.09.2022. | |
| **Lucentis - ranibizumab - EMEA/H/C/000715/II/0098**<br>Novartis Europharm Limited, Rapporteur: Kristina Dunder, "Update of section 4.6 of the SmPC in order to update information on breastfeeding following the PRAC Recommendation (EMEA/H/C/PSUSA/00002609/202010) based on a cumulative assessment of pre-clinical studies, pharmacokinetic data, published literature and post-marketing spontaneous reports.<br>The Package Leaflet is updated accordingly."<br>Request for Supplementary Information adopted on 02.06.2022. | |
| **Lumeblue - methylthioninium chloride - EMEA/H/C/002776/II/0004**<br>Alfasigma S.p.A., Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 4.2 and 5.2 of the SmPC in order to introduce a new posology regimen based on scientific literature." | |
| **Lumykras - sotorasib - EMEA/H/C/005522/II/0003**<br>Amgen Europe B.V., Rapporteur: Alexandre Moreau, "Update of section 4.2 of the SmPC based on results from the enteral feeding tube in vitro study (RPT-574024), undertaken to assess the feasibility of administration of sotorasib 120 mg film-coated tablets through an enteral feeding tube. The Package Leaflet was updated accordingly." | |
| **Lumykras - sotorasib - EMEA/H/C/005522/II/0004**<br>Amgen Europe B.V., Rapporteur: Alexandre Moreau, "Update of section 4.5 of the SmPC based on the results of study 2020042, a phase 1 clinical drug interaction study undertaken to assess the effect of concomitant sotorasib administration on the systemic exposure of breast cancer resistance protein (BCRP) transporter substrates. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet." | |
| **Lysodren - mitotane - EMEA/H/C/000521/II/0026**<br>HRA Pharma Rare Diseases, Rapporteur: Blanca | Request for supplementary information adopted with a specific timetable. |

| | |
|---|---|
| Garcia-Ochoa, "Update of sections 4.4 and 4.8 of the SmPC new safety information regarding skin reactions (including rash, pruritus, urticaria…) and estrogenic effects in children based on post-marketing safety report and literature. The Package Leaflet is updated accordingly."<br>Request for Supplementary Information adopted on 01.09.2022. | |
| **Neuraceq - florbetaben (18F) - EMEA/H/C/002553/II/0038**<br>Life Radiopharma Berlin GmbH, Rapporteur: Maria Concepcion Prieto Yerro, "Update of sections 4.4 and 5.1 of the SmPC in order to include information on the possibility of quantitative assessment as an adjunct to visual read of Neuraceq scans based on final results from study titled "Evaluation of quantitative assessment of florbetaben (18F) PET scans as an adjunct to visual assessment". This is a retrospective data analysis to evaluate florbetaben PET quantification as an adjunct to the approved visual assessment method."<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 16.06.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Orladeyo - berotralstat - EMEA/H/C/005138/II/0006**<br>BioCryst Ireland Limited, Rapporteur: Jayne Crowe, "Update of sections 4.4 and 4.5 of the SmPC in order to remove the warning for women of childbearing potential and amend drug-drug interaction information with desogestrel based on final results from study BCX7353-111; this is a phase 1 drug interaction study to evaluate the effects of berotralstat on the pharmacokinetics of a combination oral contraceptive, desogestrel with ethinyl estradiol; the Package Leaflet is updated accordingly."<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 23.06.2022, 12.05.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0008** | |

| | |
|---|---|
| Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Submission of the final report from study PMAR-EQDD-C467a-DP4-1323, listed as a legally binding measure. This is an updated population pharmacokinetics module results including PK data from the patients enrolled in the EPIC-HR study of Paxlovid."<br>Request for Supplementary Information adopted on 16.06.2022. | |
| **Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0015**<br>Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Submission of an exploratory lipid analysis conducted retrospectively using the left-over safety and PK samples from the multiple ascending dose (PART-2) of study C4671001 (phase I randomised controlled trial) submitted as part of the initial marketing authorisation."<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0016/G**<br>Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of section 4.8 of the SmPC in order to include the adverse reactions nausea, abdominal pain and malaise based on global safety database of the MAH and Literature Review.<br>The Package Leaflet is updated accordingly."<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0017**<br>Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Submission of the final report from study In Vivo Efficacy Of Pf-07321332 As A Single Agent Or In Combination With Ritonavir In | Request for supplementary information adopted with a specific timetable. |

| | |
|---|---|
| Balb/C Mouse-Adapted Sars-Cov-2 Model (PAM 023).<br>The objective of this study was to evaluate whether Ritonavir has in vivo antiviral activity against SARS-CoV-2 and whether combination of Ritonavir with PF-07321332 increased the exposure of PF-07321332 in the mouse model and further decreased viral lung replication."<br>Request for Supplementary Information adopted on 01.09.2022. | |
| **Qarziba - dinutuximab beta - EMEA/H/C/003918/II/0043, Orphan**<br>EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik, "Update of sections 4.1, 4.2 and 5.1 of the SmPC based on final results from study APN311-202V3 listed as a Specific Obligation in the Annex II of the Product Information. This is a Phase I/II dose schedule finding study of Ch14.18/CHO continuous infusion combined with subcutaneous aldesleukin (IL-2) in patients with primary refractory or relapsed neuroblastoma. In addition, the MAH took the opportunity to update Annex II section E. The Package Leaflet is updated accordingly." | See 9.1 |
| **Qarziba - dinutuximab beta - EMEA/H/C/003918/II/0044, Orphan**<br>EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik, "Update of sections 4.2 and 4.8 of the SmPC with new safety information regarding central nervous system toxicity based on post-marketing safety report and literature." | |
| **QUVIVIQ - daridorexant - EMEA/H/C/005634/II/0004/G**<br>Idorsia Pharmaceuticals Deutschland GmbH, Rapporteur: Alexandre Moreau, "Submission of the final report from studies BA-17.030 (Validation of an analytical method for the determination of ACT-541468 and its metabolites ACT-776063, ACT-776537 and ACT-1016-3307 in rat plasma samples by LC-MS/MS) and study BA-18.023 (Validation of an analytical method for the determination of ACT-541468 and its metabolites ACT-776063, ACT-776537 and ACT-1016-3307 in rabbit plasma samples by LC-MS/MS). Both studies are part of the same post-authorisation measure evaluating the long-term stability of daridorexant and its | Positive Opinion adopted by consensus on 08.09.2022. |

| | |
|---|---|
| metabolites (ACT-776063, ACT776537 and ACT-1016-3307) in rat and rabbit."<br>Opinion adopted on 08.09.2022. | |
| **Reblozyl - luspatercept - EMEA/H/C/004444/II/0011, Orphan**<br>Bristol-Myers Squibb Pharma EEIG, Rapporteur: Daniela Philadelphy, "Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to include new safety information about Extramedullary Hematopoietic Masses in transfusion-dependent beta-thalassemia patients based on the open-label phase of the ACE-536-B-THAL-001 Phase III study, the long-term follow-up study and post-marketing data. The Package Leaflet is updated accordingly." | |
| **REKAMBYS - rilpivirine - EMEA/H/C/005060/II/0008**<br>Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.4 and 5.1 of the SmPC in order to update efficacy and safety information based on week 96 results from the clinical study 207966 (ATLAS-2M). This is an open-label, randomized, Phase IIIb trial to demonstrate non-inferior antiviral activity and safety of CAB + RPV Q8W compared with CAB + RPV Q4W. Supporting Cabotegravir (CAB) Long-acting Injectable (LA) + Rilpivirine (RPV) LA every 2 months (Q8W) dosing regimen for the treatment of HIV-1 infection."<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 23.06.2022, 16.12.2021. | Positive Opinion adopted by consensus on 01.09.2022. |
| **REKAMBYS - rilpivirine - EMEA/H/C/005060/II/0012**<br>Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, "Update of section 4.2 of the SmPC in order to expand oral bridging options for missed planned injections of cabotegravir and rilpivirine based on studies 201584 (FLAIR), 207966 (ATLAS-2M), 200056 (LATTE 2) and 201585 (ATLAS).<br>The Package Leaflet is updated accordingly.<br>In addition, MAH is taking this opportunity to introduce editorial changes."<br>Request for Supplementary Information adopted on 21.07.2022. | |
| **Revlimid - lenalidomide - EMEA/H/C/000717/II/0122** | |

| | |
|---|---|
| Bristol-Myers Squibb Pharma EEIG, Rapporteur: Alexandre Moreau, "Update of section 4.2 of the SmPC to update the dosage for patients with impaired renal function (severe renal impairment and end stage renal disease) for the follicular lymphoma (FL) indication based on additional PK analysis. In addition, the MAH proposed to update the existing warning in section 4.4 of the SmPC to highlight, that male patients should not donate semen or sperm during treatment and for at least seven days after the end of treatment in order to align with the Revlimid Annex IID requirements for the patient educational brochures and to align with similar wording in the Imnovid (pomaldiomide) and Thalidomide BMS (thalidomide) SmPCs. The Package Leaflet is updated accordingly."<br>Request for Supplementary Information adopted on 22.04.2022. | |
| **Rozlytrek - entrectinib - EMEA/H/C/004936/II/0012**<br>Roche Registration GmbH, Rapporteur: Armando Genazzani, "Submission of the final integrated analysis report for cardiac risks, listed as a category 3 study in the RMP, in order to fulfil MEA/003. This is an integrated safety analysis report to assess cardiac risks based on GO40782 [STARTRK-2], CO40778 [STARTRK-NG], and BO41932 [TAPISTRY] studies (PAESs)." | |
| **Simponi - golimumab - EMEA/H/C/000992/II/0107**<br>Janssen Biologics B.V., Rapporteur: Kristina Dunder, "Submission of the final report from study MK-8259-038 (Go-BACK) in order to fulfil MEA/30.2. This is a phase 4, randomized, double-blind, parallel-group, withdrawal, post-authorisation efficacy study (PAES) of golimumab in adult participants, aged 18 to 45 years, with active non-radiographic axial spondyloarthritis."<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **Soliris - eculizumab - EMEA/H/C/000791/II/0122, Orphan**<br>Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa, "Submission of the final report from study ECU-NMO-302, a phase III, open-label, extension trial of ECU-NMO-301 to evaluate the | |

| | |
|---|---|
| safety and efficacy of eculizumab in subjects with neuromyelitis optica spectrum disorder (NMOSD) following procedure II/0105." | |
| **Spikevax - elasomeran - EMEA/H/C/005791/II/0066**<br>Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.5 and 5.1 of the SmPC in order to introduce new clinical data regarding the co-administration of Spikevax with a high-dose quadrivalent influenza vaccine (QIV-HD), based on final results from study QHD00028 (NCT04969276), a Phase II, Open-label Study to 'Assess the Safety and Immunogenicity of Fluzone High-Dose Quadrivalent (Influenza Vaccine), 2021-2022 Formulation and a Third Dose of Moderna COVID-19 Vaccine (mRNA-1273 Vaccine) Administered Either Concomitantly or Singly in Adults 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine'."<br>Request for Supplementary Information adopted on 21.07.2022. | |
| **Trecondi - treosulfan - EMEA/H/C/004751/II/0016, Orphan**<br>medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Fátima Ventura, "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study MC-FludT.14/L Trial II; a phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens.<br>The Package Leaflet is updated accordingly."<br>Request for Supplementary Information adopted on 01.09.2022, 23.06.2022. | Request for supplementary information adopted with a specific timetable. |
| **Tygacil - tigecycline - EMEA/H/C/000644/II/0121**<br>Pfizer Europe MA EEIG, Rapporteur: Blanca Garcia-Ochoa, "Update of section 5.1 of the SmPC in order to reflect updated breakpoint tables regarding antimicrobial susceptibility testing (EUCAST).<br>In addition, the MAH is taking the opportunity to update section 4.6 of the SmPC to remove | |

| | |
|---|---|
| reference to "pharmacodynamic/toxicological" data and update the contact details of the local representatives in the Package Leaflet."<br>Request for Supplementary Information adopted on 19.05.2022. | |
| **Veltassa - patiromer - EMEA/H/C/004180/II/0029**<br>Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Jayne Crowe, "Update of sections 4.2 and 4.5 of the SmPC in order to introduce new drug-drug interaction information based on results from four in vitro studies: RLY-TR-0174, titled "In Vitro Evaluation of Potential RLY5016S and Immunosuppressant Drug-Drug Interactions"; RLY-TR-0184 (titled "In Vitro Evaluation of Potential Drug-Drug Interactions Between Patiromer and Sevelamer Hydrochloride"); "In Vitro Evaluation of Drug-Drug Interactions of commonly prescribed renal and cardiovascular Drugs with Patiromer DS" and "Drug-drug interactions of commonly prescribed renal and cardiovascular Drugs with Patiromer DS in a simulated GI tract passage study". The Package Leaflet is updated accordingly."<br>Request for Supplementary Information adopted on 01.09.2022, 19.05.2022. | Request for supplementary information adopted with a specific timetable. |
| **Venclyxto - venetoclax - EMEA/H/C/004106/II/0042**<br>AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to update data supporting the efficacy of the combined regimen of obinutuzumab and venetoclax (VEN+G; also known as GDC-0199 or ABT-199) versus obinutuzumab plus chlorambucil (GClb) in previously untreated CLL patients based on final results from study BO25323/CLL14; this is a prospective, open-label, multicenter randomized phase 3 trial to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax (GDC-0199/ABT-199) versus obinutuzumab and chlorambucil in previously untreated patients with CLL and coexisting medical conditions. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." | |
| **Vocabria - cabotegravir - EMEA/H/C/004976/II/0008** | Positive Opinion adopted by consensus on |

| | |
|---|---|
| ViiV Healthcare B.V., Rapporteur: Jean-Michel Race, "Update of sections 4.4 and 5.1 of the SmPC in order to update efficacy and safety information based on week 96 results from the clinical study 207966 (ATLAS-2M). This is an open-label, randomized, Phase IIIb trial to demonstrate non-inferior antiviral activity and safety of CAB + RPV Q8W compared with CAB + RPV Q4W. Supporting Cabotegravir (CAB) Long-acting Injectable (LA) + Rilpivirine (RPV) LA every 2 months (Q8W) dosing regimen for the treatment of HIV-1 infection."<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 23.06.2022, 16.12.2021. | 01.09.2022. |
| **Vocabria - cabotegravir - EMEA/H/C/004976/II/0012**<br>ViiV Healthcare B.V., Rapporteur: Jean-Michel Race, "Update of section 4.2 of the SmPC to introduce an alternative oral therapy for bridging between planned missed injections of cabotegravir and rilpivirine (monthly and every 2 months), based on a retrospective safety analysis of pooled data from 29 subjects in 3 clinical studies (Phase III studies: 201584, 207966, and 200056). In addition, the Package Leaflet is updated accordingly.<br>The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet."<br>Request for Supplementary Information adopted on 21.07.2022. | |
| **Xevudy - sotrovimab - EMEA/H/C/005676/II/0004**<br>Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, "Submission of the final report from study PC-7831-0126 in order to fulfil the recommendation by the CHMP to submit an in vivo study in hamsters challenged with the alpha (B.1.1.7) SARS-CoV-2 variant."<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Xevudy - sotrovimab - EMEA/H/C/005676/II/0007**<br>Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 5.1 and 5.2 of the SmPC based on final results from study COMET-ICE (214367; VIR-7831-5001); this is a Phase II/III | |

| | |
|---|---|
| randomised, multi-centre, double-blind, placebo-controlled study to assess the safety and efficacy of monoclonal antibody VIR-7831 for the early treatment of coronavirus disease 2019 (COVID-19) in non-hospitalised patients." | |
| **Zercepac - trastuzumab - EMEA/H/C/005209/II/0020**<br>Accord Healthcare S.L.U., Rapporteur: Sol Ruiz, "Submission of the final report from study HLX02-BC01 in order to fulfil REC/006. This is a double-blind, randomised, parallel-controlled, multicentre, international, phase 3 study to compare the efficacy, safety, and immunogenicity of HLX02 versus EU-sourced Herceptin in combination with docetaxel."<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **WS2244**<br>**Nuwiq-EMEA/H/C/002813/WS2244/0048**<br>**Vihuma-EMEA/H/C/004459/WS2244/0030**<br>Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.8 and 5.1 of the SmPC in order to add safety and efficacy data based on the final CSR from the category 3 study GENA-21b; a prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of personalized prophylaxis with Human-cl rhFVIII in previously treated adult patients with severe haemophilia A. Further, upon request by the CHMP following the assessment of study GENA-05 (P46 013 and P46 014), the MAH is updating the numbers of evaluated subjects in SmPC section 4.8 and is removing the sentence "A prospective open-label clinical study in PUPs with severe haemophilia A (<1% FVIII:C) is ongoing" in section 5.1 of the SmPC. The Package Leaflet is updated accordingly."<br>Request for Supplementary Information adopted on 01.09.2022, 16.06.2022, 05.05.2022. | Request for supplementary information adopted with a specific timetable. |
| **WS2289**<br>**OPDIVO-EMEA/H/C/003985/WS2289/0122**<br>**Yervoy-EMEA/H/C/002213/WS2289/0099**<br>Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Blanca Garcia-Ochoa, "To update sections 4.8 and 5.1 of the SmPC to include 7.5 years of minimum follow-up for all subjects | Positive Opinion adopted by consensus on 01.09.2022. |

| | |
|---|---|
| based on addendum 04 Clinical Study Report for study CA209067; this is a phase 3 randomized, double-blind study of nivolumab monotherapy or nivolumab in combination with ipilimumab versus ipilimumab monotherapy in subjects with previously untreated, unresectable melanoma. The MAH has taken the opportunity to introduce minor editorial revisions in the SmPC."<br>Opinion adopted on 01.09.2022. | |
| **WS2304/G**<br>**Exviera-**<br>**EMEA/H/C/003837/WS2304/0054/G**<br>**Viekirax-**<br>**EMEA/H/C/003839/WS2304/0066/G**<br>AbbVie Deutschland GmbH & Co. KG, Lead Rapporteur: Filip Josephson, "Submission of the final reports from studies M14-423 (TOPAZ-1) and M14-222 (TOPAZ-II) listed as category 3 studies in the RMP for Viekirax and Exviera in order to fulfil MEA/018 for Viekirax and MEA/016 for Exviera. These are phase 3, open-label, multicentre, post-authorisation safety studies (PASS) to evaluate long-term outcomes with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin (RBV) in adults with GT1 chronic HCV infection."<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **WS2312**<br>**Kisplyx-EMEA/H/C/004224/WS2312/0053**<br>**Lenvima-**<br>**EMEA/H/C/003727/WS2312/0048**<br>Eisai GmbH, Lead Rapporteur: Karin Janssen van Doorn, "To update of SmPC sections 4.2 and 6.6 to include the option of administering the capsules as a suspension, including instructions for the administration and preparation of the suspension. The MAH also took the opportunity to include some editorial changes to the SmPC." | |

### B.5.3. CHMP-PRAC assessed procedures

| | |
|---|---|
| **Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0006**<br>Pfizer Europe MA EEIG, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Jean-Michel Dogné, "Update of sections 4.5, 4.8 and 5.1 of the SmPC based on final results from study | Request for supplementary information adopted with a specific timetable.<br><br>See 9.1 |

| | |
|---|---|
| B7471026 listed as a category 3 study in the RMP; this is a Phase III, randomized, double-blind trial to describe the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine when coadministered with a booster dose of BNT162b2 in adults 65 years of age and older; the Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted."<br>Request for Supplementary Information adopted on 01.09.2022. | |
| **Caprelsa - vandetanib - EMEA/H/C/002315/II/0043**<br>Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "C.I.4 Update of section 5.1 of the SmPC in order to update pharmacodynamic information based on interim results from study D4200C00104, listed as a specific obligation in the Annex II. This is an observational study (including a retrospective arm to evaluate the Benefit/Risk of vandetanib (Caprelsa) 300 mg in RET mutation negative and RET mutation positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic thyroid cancer (MTC)), to confirm the efficacy and safety of Caprelsa in RET-negative patients with the aim to fulfil SOB001 and convert Caprelsa from conditional to normal Marketing Authorization.<br>In addition, the MAH takes to opportunity to rectify the Dutch translation of the Caprelsa Product Information."<br>Request for Supplementary Information adopted on 19.05.2022, 16.12.2021, 24.06.2021, 28.05.2020. | See 9.1 |
| **Cibinqo - abrocitinib - EMEA/H/C/005452/II/0001**<br>Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.4 and 4.8 of the SmPC based on updated safety data from the Full Cumulative Pool (April 2021 data cut) from the ongoing long-term extension study B7451015.The RMP version v1.0 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes in the SmPC and to update the contact details of the local representatives in the Package | Positive Opinion adopted by consensus on 01.09.2022. |

| | |
|---|---|
| Leaflet."<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 07.07.2022, 07.04.2022. | |
| **COMIRNATY - tozinameran - EMEA/H/C/005735/II/0140**<br>BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst"Addition of a new strain (Omicron BA.1) resulting in a new Comirnaty Original/Omicron BA.1 (15 µg tozinameran/ 15 µg riltozinameran)/dose dispersion for injection presentation. The Annex A, the SmPC, the Labelling and the Package Leaflet are updated accordingly. A revised RMP version 6.1 has been approved."<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022.<br><br>See 9.1 |
| **COMIRNATY - tozinameran - EMEA/H/C/005735/II/0141**<br>BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.4 and 4.8 of the SmPC in order to update the occurrence of myocarditis because more information is available in the age group 5-11 years; and to update the statement in the SmPC section 4.4 regarding the risk of myocarditis after a third dose of Comirnaty based on real-world evidence requested by PRAC following the assessment of MEA/002.13 procedure. The package leaflet is updated accordingly.<br>In addition, the MAH took the opportunity to implement editorial changes in section 4.4 of the SmPC." | |
| **COMIRNATY - tozinameran - EMEA/H/C/005735/II/0143**<br>BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst"Addition of a new strain (Omicron BA.4-5) resulting in a new Comirnaty bivalent Original/Omicron BA.4-5 (15 µg / 15 µg per dose) dispersion for injection presentation. The SmPC, the Package Leaflet and Labelling are updated accordingly. The submission includes a revised RMP version 7.0." | See 9.1 |
| **Dapivirine Vaginal Ring 25 mg - dapivirine - EMEA/H/W/002168/II/0015/G**<br>International Partnership for Microbicides | Positive Opinion adopted by consensus on 01.09.2022. |

| | |
|---|---|
| Belgium AISBL, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Jan Neuhauser, "Submission of the four addenda from studies IPM 032, MTN-025, IPM 007 and MTN-015 listed as category 3 studies in the RMP. The data presented in the addenda are the results of retrospective next generation sequencing (NGS) and phenotype susceptibility testing on blood samples to further assess the potential development of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in women with unrecognized or acute HIV-1 infection. The tested samples are all from women who were initially enrolled in the Phase III clinical trials IPM 027 and MTN-020 and then had the option to participate in the open-label extension (OLE) studies IPM 032 and MTN-025. If the women became infected with HIV during any of the trials, they could enrol in the observational studies IPM 007 and MTN-015. The RMP version 0.9 has also been submitted. Additionally, the MAH would like to take the opportunity to update the EMA on other commitments outlined in the RMP as additional risk minimisation measures. These include the development of a Healthcare Professional Guide (HCP Guide) and a User Guide with agreed objectives and key messages."<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 07.04.2022. | |
| **Deltyba - delamanid - EMEA/H/C/002552/II/0053, Orphan**<br>Otsuka Novel Products GmbH, Rapporteur: Christophe Focke, PRAC Rapporteur: Jo Robays, "Update of section 4.8 of the SmPC in order to update the list of adverse drug reactions (ADRs table) following the development of an improved methodology to identify relevant ADRs likely attributable to delamanid. The section 4 of the Package Leaflet is updated accordingly. The RMP version 4.1 has also been submitted."<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 05.05.2022, 13.01.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **JEMPERLI - dostarlimab - EMEA/H/C/005204/II/0013**<br>GlaxoSmithKline (Ireland) Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Marcia | Request for supplementary information adopted with a specific timetable. |

| | |
|---|---|
| Sofia Sanches de Castro Lopes Silva, "Update of section 5.1 of the SmPC in order to update efficacy and safety information based on interim results from study 4010-01-001 (GARNET) listed as a specific obligation in the Annex II; This is a single-arm, open-label, phase I trial of intravenous dostarlimab in advanced solid tumours. In addition, the MAH took the opportunity to update section E of Annex II. The RMP version 1.2 has also been submitted." Request for Supplementary Information adopted on 01.09.2022. | |
| **Jorveza - budesonide - EMEA/H/C/004655/II/0015, Orphan** Dr. Falk Pharma GmbH, Rapporteur: Martina Weise, PRAC Rapporteur: Zane Neikena, "Update of section 4.8 of the SmPC in order to update the list of adverse reactions based on final results from the long-term maintenance study BUL-2/EER; this is a double-blind, randomized, placebo-controlled, phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets vs. placebo for maintenance of clinico-pathological remission in adult patients with eosinophilic esophagitis. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 3.0 has also been submitted. The MAH also submitted the final report of study BUL-6/BIO, which was previously assessed within the scope of extension EMEA/H/C/004655/X/0007/G as applicant's response to CHMP Day 120 List of Questions." Request for Supplementary Information adopted on 19.05.2022. | |
| **Jyseleca - filgotinib - EMEA/H/C/005113/II/0018** Galapagos N.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.4, 4.6 and 5.1 of the SmPC in order to update information on fertility based on interim results from studies GLPG0634-CL-227 (MANTA Ray) and GS-US-418-4279 (MANTA) listed as a category 3 study in the RMP. The Package Leaflet and Annex II are updated | Request for supplementary information adopted with a specific timetable. |

| | |
|---|---|
| accordingly. The RMP version 4.1 has also been submitted."<br>Request for Supplementary Information adopted on 01.09.2022. | |
| **Kaftrio - ivacaftor / tezacaftor / elexacaftor - EMEA/H/C/005269/II/0024, Orphan**<br>Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on interim results from clinical study VX17-445-105 (study 105) listed as a category 3 study in the RMP; this is a Phase III, open label extension study to evaluate the long-term safety and efficacy of ELX/TEZ/IVA in CF subjects homozygous for F508del (F/F genotype) or heterozygous for F508del and a minimal function (MF) mutation (F/MF genotypes).<br>The RMP version 6.1 has also been submitted. In addition, the MAH took the opportunity to implement minor corrections (section 5.3 and 6.5); as well as editorial changes to the SmPC. The requested variation proposed amendments to the Summary of Product Characteristics and to the Risk Management Plan (RMP)."<br>Request for Supplementary Information adopted on 01.09.2022, 10.06.2022. | Request for supplementary information adopted with a specific timetable. |
| **Leqvio - inclisiran - EMEA/H/C/005333/II/0013**<br>Novartis Europharm Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Kimmo Jaakkola, "Submission of the final report from ORION-3 study (CKJX839A12201E1 or MDCO-PCS-16-01) listed as a category 3 study in the RMP. This is an open label, active comparator extension trial to assess the effect of long-term dosing of inclisiran and evolocumab given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C. The RMP version 2.0 has also been submitted."<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Lorviqua - lorlatinib - EMEA/H/C/004646/II/0022**<br>Pfizer Europe MA EEIG, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Nikica Mirošević Skvrce, "Submission of an updated RMP version 5.0 to revise plans for conduct of hepatic | |

| | |
|---|---|
| impairment studies.<br>The RMP is updated to reflect the hepatic impairment study B7461009 "A Phase 1 Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Lorlatinib in Advanced Cancer Patients" termination and to include new hepatic impairment study B7461040 "A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate The Plasma Pharmacokinetics and Safety of Lorlatinib in Participants with Moderate and Severe Hepatic Impairment Relative to Participants with Normal Hepatic Function"."<br>Request for Supplementary Information adopted on 21.07.2022. | |
| **MenQuadfi - meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/005084/II/0018/G**<br>Sanofi Pasteur, Rapporteur: Andrea Laslop, PRAC Rapporteur: Jean-Michel Dogné, "Update of sections 4.2, 4.5, 4.8 and 5.1 of the SmPC in order to add long-term antibody persistence at least 3 years after primary vaccination, immunogenicity and safety of a booster dose of MenQuadfi in adolescents, adults, and older adults, as well as co-administration data with meningococcal serogroup B vaccine in adolescents and adults, in order to fulfil ANX/002 and ANX/003 based on final results from studies MET59 and MEQ00066, respectively, listed as specific obligations in the Annex II. MET59 is a phase 3b, open-label, partially randomized, parallel-group, active-controlled, multi-center study evaluating the immunogenicity and safety of a booster dose of an investigational quadrivalent MenACYW conjugate vaccine in adolescents and adults, while MEQ00066 is a phase 3, two-stage, randomized, open-label, multi-center trial evaluating the safety and immunogenicity of a single dose of MenACYW conjugate vaccine at least 3 years following initial vaccination with either Menomune vaccine or MenACYW conjugate vaccine in older adults. The Annex II and Package Leaflet are updated accordingly. The RMP version 1.1 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." | |
| **Mysimba - naltrexone hydrochloride /** | See 9.1 |

| | |
|---|---|
| **bupropion hydrochloride - EMEA/H/C/003687/II/0056**<br>Orexigen Therapeutics Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, "Submission of updated study design and protocol synopsis for CVOT-2 study, a category 1 study listed in Annex II.D (ANX/001.7) undertaken to assess the effect of naltrexone extended release (ER) / bupropion ER on the occurrence of major adverse cardiovascular events (MACE), as requested in the CHMP AR for ANX/001.6. The Annex II and the RMP version 13 are updated accordingly."<br>Request for Supplementary Information adopted on 24.03.2022. | |
| **NUBEQA - darolutamide - EMEA/H/C/004790/II/0012**<br>Bayer AG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Jan Neuhauser, "Submission of the final report of carcinogenicity study T104877-7 listed as a category 3 study in the RMP. This is a non-clinical study to assess the carcinogenic potential in mice. The study evaluates the effects of daily oral administration of darolutamide for a period of 6 months in tg-rasH2 transgenic mouse model.<br>The updated RMP version 3.1 has also been submitted."<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0014**<br>Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to include a 0.5 mL third dose for Nuvaxovid, to boost subjects that have previously completed a primary vaccination series with Nuvaxovid (homologous booster dose) or with an authorised mRNA or adenoviral vector vaccine (heterologous booster dose), based on interim data from study 2019nCoV-101 (Part 2), a Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein | Positive Opinion adopted by consensus on 01.09.2022.<br><br>See 9.1 |

| | |
|---|---|
| Nanoparticle Vaccine (SARS-CoV-2 rS) With or Without Matrix-M Adjuvant in Healthy Subjects (NCT04368988), final data from study 2019nCoV-501, a Phase 2a/b, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV (NCT04533399) and data from the COV-BOOST study (Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial); the Package Leaflet is updated accordingly. The RMP version 1.2 has also been submitted. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to make minor editorial corrections throughout the product information."<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 21.07.2022. | |
| **Oxlumo - lumasiran - EMEA/H/C/005040/II/0008, Orphan**<br>Alnylam Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Mari Thorn, "Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to clarify administration instructions, remove an existing warning on metabolic acidosis in patients with severe or end stage renal impairment, update the description of adverse reactions injection site reactions, abdominal pain and immunogenicity, update efficacy, pharmacokinetic information based on interim results from a category 3 study in the RMP ILLUMINATE-C (ALN-GO1-005): A single arm study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1) and, in addition, based on available long-term efficacy and safety data from ongoing phase 3 studies ALN-GO1-003 in PH1 patients >6 years old and ALN-GO1-004 in PH1 patients <6 years old, and open-label extension study ALN-GO1-002. The Package Leaflet is updated accordingly. The RMP | |

| | |
|---|---|
| version 1.1 has also been submitted."<br>Request for Supplementary Information adopted on 23.06.2022, 24.02.2022. | |
| **Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0007**<br>Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber, "Submission of the final report from study C4671010 listed as a category 3 study in the RMP. This is a phase I, non-randomized, open label study to assess the pharmacokinetics, safety and tolerability of PF-07321332 boosted with ritonavir in adults with moderate hepatic impairment and individuals with normal hepatic function. The RMP version 2.0 has also been submitted."<br>Request for Supplementary Information adopted on 01.09.2022, 10.06.2022. | Request for supplementary information adopted with a specific timetable. |
| **QINLOCK - ripretinib - EMEA/H/C/005614/II/0004, Orphan**<br>Deciphera Pharmaceuticals (Netherlands) B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Željana Margan Koletić, "Update of sections 4.2 and 5.2 of the SmPC in order to change posology recommendations in patients with hepatic impairment and update the description of pharmacokinetics based on final results from study DCC-2618-01-004; a Phase 1 study of the Pharmacokinetics, Safety, and Tolerability of Ripretinib in Subjects With Hepatic Impairment Compared to Healthy Control Subjects. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted." | |
| **RINVOQ - upadacitinib - EMEA/H/C/004760/II/0020/G**<br>AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on 'Hypersensitivity' and add it to the list of adverse drug reactions (ADRs) with frequency not known. The MAH also proposed to update section 4.8 of the SmPC in order to add 'Non-Melanoma Skin Cancer (NMSC)' to the list of adverse drug reactions (ADRs) with frequency | |

| | |
|---|---|
| uncommon. The Package Leaflet has been updated accordingly. The RMP version 9.0 has also been submitted."<br>Request for Supplementary Information adopted on 10.06.2022. | |
| **Rubraca - rucaparib - EMEA/H/C/004272/II/0029**<br>Clovis Oncology Ireland Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Ulla Wändel Liminga, "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on final results from study CO-338-043 (ARIEL4); this is a phase 3, multicentre, open-label, randomised study evaluating the efficacy and safety of rucaparib versus chemotherapy for treatment of relapsed ovarian cancer listed as a specific obligation in the Annex II; the Package Leaflet is updated accordingly. The RMP version 6.1 has also been submitted. With this variation application, the MAH requests for the Rubraca marketing authorisation to no longer be subject to specific obligations. The SmPC, Annex II and PL are updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes and bring the PI in line with the latest QRD template version 10.2 Rev.1."<br>Request for Supplementary Information adopted on 21.07.2022, 24.03.2022, 11.11.2021. | See 9.1 |
| **Rydapt - midostaurin - EMEA/H/C/004095/II/0024, Orphan**<br>Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "C.I.11.b Submission of the final report from study CPKC412E2301 listed as an obligation in the Annex II of the Product Information. This is a Phase III study to investigate the efficacy in elderly patients. A final pharmacogenomic report is also provided to fulfil MEA004. The Annex II and the RMP (submitted version 7.0) are updated accordingly."<br>Request for Supplementary Information adopted on 07.07.2022, 10.03.2022. | |
| **Spikevax - elasomeran - EMEA/H/C/005791/II/0075/G**<br>Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "B.I.a.6.a (Type II): Addition of a new strain (Omicron | Positive Opinion adopted by consensus on 01.09.2022.<br>See 9.1 |

| | |
|---|---|
| BA.1) resulting in two new Spikevax bivalent Original/Omicron (25 µg elasomeran / 25 µg imelasomeran per dose) 0.1 mg/mL dispersion for injection presentations. The SmPC, the Package Leaflet and Labelling are updated accordingly. The submission includes a revised RMP version 4.2.<br>Opinion adopted on 01.09.2022. | |
| **Symtuza - darunavir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004391/II/0045**<br>Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins, "Submission of the interim report from study GS-US-292-0106 listed as a category 3 study in the RMP. This is a Phase II/III, open-label study to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) single tablet regimen in HIV-1 infected antiretroviral treatment-naive adolescents and virologically suppressed HIV-infected children. The RMP version 8.1 has also been submitted."<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0075**<br>AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, "Update of section 5.1 of the SmPC in order to include updated efficacy information based on the 6 months follow-up analysis from study D8110C00001 listed as a specific obligation in the Annex II; this is a phase III randomised, double-blind, placebo-controlled, multicenter study in adults to determine the safety, efficacy and immunogenicity of Vaxzevria. The RMP version 5.1 has also been submitted. The MAH removed the important identified risk of anaphylaxis from the list of safety concerns, updated the routine and additional pharmacovigilance activities section and took the opportunity to implement other administrative updates."<br>Request for Supplementary Information adopted on 23.06.2022. | |
| **Vemlidy - tenofovir alafenamide -** | Positive Opinion adopted by consensus on |

| | |
|---|---|
| **EMEA/H/C/004169/II/0038**<br>Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Valentina Di Giovanni, "Submission of the final week 192 report from study GS-US-320-3912; 'A Phase 2, Randomized, Open Label Study to Evaluate the Efficacy and Safety of Tenofovir Alafenamide (TAF) versus Tenofovir Disoproxil Fumarate (TDF)–containing Regimens in Subjects with Chronic HBV Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant', listed as a category 3 study in the RMP.<br>The RMP version 9.0 has also been submitted."<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 10.06.2022. | 01.09.2022. |
| **Vumerity - diroximel fumarate - EMEA/H/C/005437/II/0005**<br>Biogen Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, "Submission of the final report from study ALK8700-A301, A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis listed as a category 3 study in the RMP. This is a multicentre, open-label study to evaluate the long-term safety, tolerability, and treatment effect over time of DRF administered for up to 96 weeks in adult participants with RRMS.<br>The RMP version 1.1 has also been submitted."<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **Vyndaqel - tafamidis - EMEA/H/C/002294/II/0081, Orphan**<br>Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Tiphaine Vaillant, "Update of section 5.1 of the SmPC in order to update information based on final results from study B3461029 listed as a Specific Obligation in the Annex II of the Product Information. This is a non-interventional PASS sub-study evaluating effects of tafamidis on disease progression in patients with non-Val30Met mutations and symptomatic neuropathy. Consequently, the MAH proposes a switch from marketing authorisation under exceptional circumstances to full marketing authorisation | |

| | |
|---|---|
| given the fulfilment of the SOB. The Annex II and Package Leaflet are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."<br>Request for Supplementary Information adopted on 21.07.2022. | |
| **WS2187**<br>**OPDIVO-**<br>**EMEA/H/C/003985/WS2187/0121**<br>**Yervoy-EMEA/H/C/002213/WS2187/0098**<br>Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Blanca Garcia-Ochoa, Lead PRAC Rapporteur: Brigitte Keller-Stanislawski,<br>"Update of section 4.8 of the SmPC in alignment with the recommendations made by the CHMP to revise the pooling approach used to describe irARs and tabulated summaries of ADRs following II/0096. Individual study data included within this application has been previously reviewed by the CHMP.<br>The updated Opdivo RMP version 29.0 and Yervoy RMP version 37.0 have also been submitted.<br>The MAH took the opportunity to introduce editorial changes.<br>The Package Leaflet was updated accordingly."<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **WS2274**<br>**Relvar Ellipta-**<br>**EMEA/H/C/002673/WS2274/0054**<br>**Revinty Ellipta-**<br>**EMEA/H/C/002745/WS2274/0052**<br>GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Maria del Pilar Rayon,<br>"Submission of the final report from study HZA114971 listed as a category 3 study in the RMP. This is a multicentre randomised, double-blind, placebo-controlled, parallel-group study to evaluate the effects of a one-year regimen of orally inhaled fluticasone furoate 50 mcg once daily on growth velocity in prepubertal, paediatric subjects with asthma. The RMP version 11.1 has also been submitted."<br>Request for Supplementary Information adopted on 07.07.2022. | |

| | |
|---|---|
| **WS2307**<br>**Rixathon-**<br>**EMEA/H/C/003903/WS2307/0062**<br>**Riximyo-**<br>**EMEA/H/C/004729/WS2307/0063**<br>Sandoz GmbH, Lead Rapporteur: Jan Mueller-Berghaus, Lead PRAC Rapporteur: Anette Kirstine Stark, "Update of section 4.1 of the SmPC in order to include the rapid infusion regimen (90 minutes) for second and subsequent infusions in the label for patients with non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukaemia (CLL) based on non-interventional PASS CGP2013ES01R and scientific literature.<br>The RMP version 7.0 has also been submitted." | |
| **WS2323**<br>**Juluca-EMEA/H/C/004427/WS2323/0045**<br>**Tivicay-EMEA/H/C/002753/WS2323/0081**<br>**Triumeq-**<br>**EMEA/H/C/002754/WS2323/0106**<br>ViiV Healthcare B.V., Lead Rapporteur: Janet Koenig, Lead PRAC Rapporteur: Nathalie Gault, "Submission of the final report from study 200336 listed as a category 3 study in the RMP. This is a prospective, interventional pharmacokinetic and safety study of DTG/ABC/3TC in pregnant women. The summary of objective of this PASS study is to investigate the use of DTG during pregnancy and address the safety concerns of pregnant/breastfeeding women. The RMP versions 18.0, 20.0 and 4.0 for Tivicay, Triumeq and Juluca, respectively, have also been submitted."<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |

### B.5.4. PRAC assessed procedures

| | |
|---|---|
| PRAC Led<br>**Adasuve - loxapine -**<br>**EMEA/H/C/002400/II/0033**<br>Ferrer Internacional s.a., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Revision of sections 4.2, 4.4 and 4.8 of the SmPC in order to update safety information on bronchospasm, based on the final results from study AMDC-204-401 EU PASS: a post-authorisation observational study | |

| | |
|---|---|
| to evaluate the safety of ADASUVE (Staccato loxapine for inhalation) in agitated persons in routine clinical care (category 3 study in the RMP); Annex IID of the PI, the Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.<br>Version 10.1 of the RMP has also been agreed."<br>Request for Supplementary Information adopted on 05.05.2022, 02.12.2021. | |
| PRAC Led<br>**Besremi - ropeginterferon alfa-2b - EMEA/H/C/004128/II/0025**<br>AOP Orphan Pharmaceuticals GmbH, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, PRAC-CHMP liaison: Bruno Sepodes, "Submission of an updated RMP version 1.1 for Besremi to revise safety concerns according to GVP Module V Rev.2."<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| PRAC Led<br>**Cancidas - caspofungin - EMEA/H/C/000379/II/0078**<br>Merck Sharp & Dohme B.V., PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of an updated RMP version 4.1 in order to remove safety concerns and align it with the EU GVP Module V (Revision 2)."<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| PRAC Led<br>**Cotellic - cobimetinib - EMEA/H/C/003960/II/0027**<br>Roche Registration GmbH, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Update of sections 4.4 and 5.1 of the SmPC in order to update information based on final results from study ML39302 listed as a category 3 study in the RMP in order to fulfil MEA/003.5; this is a non-interventional PASS study to investigate the effectiveness, safety and utilisation of cobimetinib and vemurafenib in patients with and without brain metastasis with BRAF V600 mutant melanoma under real world conditions. The RMP version 5.0 has also been submitted." | Request for supplementary information adopted with a specific timetable. |

| | |
|---|---|
| Request for Supplementary Information adopted on 01.09.2022. | |
| PRAC Led<br>**Gazyvaro - obinutuzumab - EMEA/H/C/002799/II/0051, Orphan**<br>Roche Registration GmbH, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Update of section 4.8 of the SmPC in line with the SmPC Guideline following the recommendation by PRAC in the outcome for the signal assessment of non-overt disseminated intravascular coagulation (DIC) (EPITT no: 19711). The Package Leaflet is updated accordingly."<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| PRAC Led<br>**Jinarc - tolvaptan - EMEA/H/C/002788/II/0036**<br>Otsuka Pharmaceutical Netherlands B.V., PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Armando Genazzani, "Submission of an updated RMP version 15.0 in order to reflect the outcome of the substantial amendment to the protocol of the category 1 PASS study (156-12-299) as concluded in (PSA/S/0078.1). The Annex II is updated accordingly. In addition, the MAH took the opportunity to correct an oversight/editorial error in the Package Leaflet relevant to (II/0033/G)."<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 10.06.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| PRAC Led<br>**Mycamine - micafungin - EMEA/H/C/000734/II/0047**<br>Astellas Pharma Europe B.V., PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "To update Annex II and the RMP to version 23.0 to include the results of the non-interventional PASS as an Effectiveness Check of the Prescriber Checklist for Mycamine (micafungin) - 9463-PV-0002."<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| PRAC Led<br>**Nplate - romiplostim - EMEA/H/C/000942/II/0083**<br>Amgen Europe B.V., Rapporteur: Maria | Positive Opinion adopted by consensus on 01.09.2022. |

| | |
|---|---|
| Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "Submission of the final report from study 20070797 listed as a category 3 study in the RMP. This is an observational study assessing the long-term safety of romiplostim treatment in real-life clinical practice in three Nordic countries. The RMP version 21.0 has also been submitted."<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 10.02.2022. | |
| PRAC Led<br>**SCENESSE - afamelanotide - EMEA/H/C/002548/II/0042, Orphan**<br>Clinuvel Europe Limited, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of an updated RMP version 9.1 in order to update the allergy and hypersensitivity risk from potential to identified, following reported cases of positive allergy test results, confirming the causal association between the allergies to afamelanotide. Consequently, the RMP has been revised to reclassify the important potential risk Allergy and hypersensitivity to important identified risk."<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| PRAC Led<br>**Stelara - ustekinumab - EMEA/H/C/000958/II/0095**<br>Janssen-Cilag International N.V., PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Jayne Crowe, "Submission of the final report from study PSOLAR (C0168Z03) listed as a category 3 study in the RMP. This is a Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics: PSOLAR. The RMP version 22.2 has also been submitted."<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |
| PRAC Led<br>**Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0038**<br>AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Christophe Focke, "Submission of the | Positive Opinion adopted by consensus on 01.09.2022. |

| | |
|---|---|
| final report from study MS1222-0003 ''Assessment of anti-PF4 antibodies prior to, and following, vaccination with AZD1222" listed as a category 3 study in the RMP. This is a study where sera of vaccinated individuals in study D8110C00001 are tested to elucidate whether vaccination with Vaxzevria leads to increased levels of circulating anti-PF4 antibodies, a key component of the hypothesised mechanism underlying thrombosis with thrombocytopenia syndrome (TTS)."<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 10.02.2022, 28.10.2021. | |
| PRAC Led<br>**VIZAMYL - flutemetamol (18F) - EMEA/H/C/002557/II/0029**<br>GE Healthcare AS, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final report from study (GE067-027) listed as a category 3 study in the RMP in addition to a comprehensive root-cause analysis on the contributing factors having an impact on reader performance as requested by PRAC. This is a non-interventional post-authorisation safety study (PASS) to evaluate the effectiveness of VIZAMYL reader training in Europe. The RMP version 3.1 has also been submitted and updated to reflect the completion of study GE067-028, previously assessed in MEA 003.3."<br>Request for Supplementary Information adopted on 01.09.2022, 10.06.2022. | Request for supplementary information adopted with a specific timetable. |
| PRAC Led<br>**WS2268 Dovato-EMEA/H/C/004909/WS2268/0031 Juluca-EMEA/H/C/004427/WS2268/0044 Tivicay-EMEA/H/C/002753/WS2268/0079 Triumeq-EMEA/H/C/002754/WS2268/0104**<br>ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "To update section 4.8 of the SmPC and section 4 of the PL to include the ADR "weight increased" with a frequency "common".<br>In addition, the marketing authorisation holder has taken the opportunity to implement a minor editorial change in the German SmPC for | Positive Opinion adopted by consensus on 01.09.2022. |

| | |
|---|---|
| Juluca.”<br>Opinion adopted on 01.09.2022.<br>Request for Supplementary Information adopted on 10.06.2022. | |
| PRAC Led<br>**WS2270**<br>**Vfend-EMEA/H/C/000387/WS2270/0147**<br>Pfizer Europe MA EEIG, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, “To update the Annex II and RMP to version 6.0 to include the results from final clinical study report (CSR) following the completion of a non-interventional (NI) post-authorisation safety study (PASS), A1501103 "An Active Safety Surveillance Program to Monitor Selected Events in Patients with Long-term Voriconazole Use" - MEA091.<br>In addition, the MAH is taking this opportunity to introduce editorial changes.”<br>Request for Supplementary Information adopted on 01.09.2022. | Request for supplementary information adopted with a specific timetable. |

**B.5.5. CHMP-CAT assessed procedures**

| | |
|---|---|
| **Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0004, ATMP**<br>Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Armando Genazzani | |
| **Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0054, ATMP**<br>Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuo, ” - To update the SmPC (section 6.6) and PIL (Thawing Imlygic vials) to revise the time for complete vial thaw from "approximately 30 minutes" to “the time to achieve complete vial thaw is expected to be 30 to 70 minutes, depending on the ambient temperature.”<br>The MAH took the opportunity to introduce minor editorial changes in section 4.8 of the SmPC.” | |
| **Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0055, Orphan, ATMP** | |

Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang
Request for Supplementary Information adopted on 17.06.2022.

**Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0056, Orphan, ATMP**

Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang,
"Update of sections 4.2 and 5.1 of the SmPC in order to update efficacy and safety information in paediatric population based on study CCTL019C2202, a phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in paediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL) (BIANCA).
The Package Leaflet is updated accordingly."
Request for Supplementary Information adopted on 17.06.2022.

**Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0061/G, Orphan, ATMP**

Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang
Opinion adopted on 09.09.2022.
Request for Supplementary Information adopted on 15.07.2022.

**Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0062, Orphan, ATMP**

Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang,
"Submission of the final report from study CCTL019B2401 listed as a category 1 study in the Annex II of the Product Information in order to fulfil ANX/007.3. This is a sub-analysis (PAES) to assess efficacy in patients with relapsed or refractory diffuse large B-cell lymphoma based on data from the registry study to assess the long-term safety of patients with B lymphocyte malignancies treated with tisagenlecleucel. The Annex II is updated accordingly."

**Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0031, Orphan, ATMP**

Novartis Europharm Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege

**WS2247**
**Tecartus-**
**EMEA/H/C/005102/WS2247/0020**
**Yescarta-**
**EMEA/H/C/004480/WS2247/0050**
Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus
Request for Supplementary Information adopted on 15.07.2022, 13.05.2022.

### B.5.6. CHMP-PRAC-CAT assessed procedures

**Kymriah - tisagenlecleucel -**
**EMEA/H/C/004090/II/0060, Orphan, ATMP**
Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of section 4.2 of the SmPC in order to update the paediatric statement for the B-cell ALL indication and section 4.4 to update the warning on 'prior treatment with anti-CD19 therapy' as well as sections 4.4 and 4.8 in order to update safety data to reflect the pool of the 3 studies B2202, B2205J and B2001X. The proposed changes are in line with the request of the CHMP following the assessment of P46/012. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to correct the Complete Response Rate (CRR) 95% Confidence Interval (CI) on Enrolled set for E2202 study presented in Table 8 in section 5.1 of the SmPC. The RMP version 5.0 has also been submitted."
Request for Supplementary Information adopted on 15.07.2022.

### B.5.7. PRAC assessed ATMP procedures

PRAC Led
**Imlygic - talimogene laherparepvec -**
**EMEA/H/C/002771/II/0056, ATMP**
Amgen Europe B.V., CHMP Coordinator: Johanna Lähteenvuo, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report from study 20120139 listed as a category

| | |
|---|---|
| 3 study in the RMP in order to fulfil MEA/004. This is a multicenter, observational registry study to evaluate the survival and long-term safety of subjects who previously received talimogene laherparepvec in Amgen or BioVEX sponsored clinical trials.” | |

### B.5.8. Unclassified procedures and worksharing procedures of type I variations

| | |
|---|---|
| **WS2277**<br>**Herceptin-**<br>**EMEA/H/C/000278/WS2277/0182**<br>**MabThera-**<br>**EMEA/H/C/000165/WS2277/0192**<br>Roche Registration GmbH, Lead Rapporteur: Jan Mueller-Berghaus<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **WS2291/G**<br>**Ambirix-**<br>**EMEA/H/C/000426/WS2291/0122/G**<br>**Twinrix Adult-**<br>**EMEA/H/C/000112/WS2291/0157/G**<br>**Twinrix Paediatric-**<br>**EMEA/H/C/000129/WS2291/0158/G**<br>GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke | |
| **WS2292**<br>**Abseamed-**<br>**EMEA/H/C/000727/WS2292/0099**<br>**Binocrit-**<br>**EMEA/H/C/000725/WS2292/0098**<br>**Epoetin alfa Hexal-**<br>**EMEA/H/C/000726/WS2292/0098**<br>Sandoz GmbH, Lead Rapporteur: Alexandre Moreau<br>Request for Supplementary Information adopted on 21.07.2022. | |
| **WS2301/G**<br>**M-M-RvaxPro-**<br>**EMEA/H/C/000604/WS2301/0117/G**<br>**ProQuad-**<br>**EMEA/H/C/000622/WS2301/0158/G**<br>Merck Sharp & Dohme B.V., Lead Rapporteur: Jan Mueller-Berghaus,<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **WS2308/G**<br>**AZILECT-**<br>**EMEA/H/C/000574/WS2308/0090/G** | |

| | |
|---|---|
| **Rasagiline ratiopharm-**<br>**EMEA/H/C/003957/WS2308/0022/G**<br>Teva B.V., Lead Rapporteur: Bruno Sepodes | |
| **WS2310**<br>**Dovato-EMEA/H/C/004909/WS2310/0033**<br>**Triumeq-**<br>**EMEA/H/C/002754/WS2310/0107**<br>ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson<br>Opinion adopted on 01.09.2022. | Positive Opinion adopted by consensus on 01.09.2022. |
| **WS2324/G**<br>**Suboxone-**<br>**EMEA/H/C/000697/WS2324/0053/G**<br>Indivior Europe Limited, Lead Rapporteur: Janet Koenig | |
| **WS2337/G**<br>**Copalia-**<br>**EMEA/H/C/000774/WS2337/0126/G**<br>**Dafiro-**<br>**EMEA/H/C/000776/WS2337/0130/G**<br>**Exforge-**<br>**EMEA/H/C/000716/WS2337/0125/G**<br>Novartis Europharm Limited, Lead Rapporteur: Thalia Marie Estrup Blicher, "C.I.z - To update section 4.9 of the SmPC, to implement the wording related to the risk of non-cardiogenic pulmonary oedema in amlodipine overdose, following finalisation of procedure PSUSA/00010434/202107.<br>C.I.11.a - To update Annex II to reflect the fulfilment of Condition B, as set out by the Commission Decision as an outcome of the assessment for the impact of the Article 5(3) scientific opinion on nitrosamines in human medicinal products on the opinion adopted pursuant to Article 31 of Directive 2001/83/EC for angiotensin-II-receptor antagonists (sartans) containing a tetrazole group."<br>Request for Supplementary Information adopted on 08.09.2022. | Request for supplementary information adopted with a specific timetable. |
| **WS2338**<br>**Copalia HCT-**<br>**EMEA/H/C/001159/WS2338/0102**<br>**Dafiro HCT-**<br>**EMEA/H/C/001160/WS2338/0104**<br>**Exforge HCT-**<br>**EMEA/H/C/001068/WS2338/0101**<br>Novartis Europharm Limited, Lead Rapporteur: | Request for supplementary information adopted with a specific timetable. |

| | |
|---|---|
| Thalia Marie Estrup Blicher, "C.I.z - To update section 4.9 of the SmPC, to implement the wording related to the risk of non-cardiogenic pulmonary oedema in amlodipine overdose, following finalisation of procedure PSUSA/00010434/202107."<br>Request for Supplementary Information adopted on 08.09.2022. | |

### B.5.9. Information on withdrawn type II variation / WS procedure

| | |
|---|---|
| **Abevmy - bevacizumab - EMEA/H/C/005327/II/0009**<br>Mylan IRE Healthcare Limited, Rapporteur: Jan Mueller-Berghaus<br>Request for Supplementary Information adopted on 16.06.2022. | The MAH withdrew the procedure on 07.09.2022. |

### B.5.10. Information on type II variation / WS procedure with revised timetable

| | |
|---|---|
| PRAC Led<br>**Duavive - estrogens conjugated / bazedoxifene - EMEA/H/C/002314/II/0032**<br>Pfizer Europe MA EEIG, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of an updated RMP version 3.2 in order to reflect the updated study milestones and completion of the post-authorisation safety study of CE/BZA in the United States (US PASS, study B2311060) previously assessed as part of II/0030 (MEA002.15), as well as to update the post-marketing data with the data lock point of 31 October 2021."<br>Request for Supplementary Information adopted on 07.07.2022. | Request by the applicant for an extension to the clock stop to respond to the RSI adopted in July 2022. |

## B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

### B.6.1. Start of procedure for New Applications: timetables for information

### B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

### B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

**sodium phenylbutyrate / ursodoxicoltaurine - EMEA/H/C/005901, Orphan**
Amylyx Pharmaceuticals EMEA B.V., treatment of amyotrophic lateral sclerosis (ALS)
List of Questions adopted on 23.06.2022.

**Byfavo - remimazolam - EMEA/H/C/005246/X/0002**
PAION Netherlands B.V., Rapporteur: Bruno Sepodes, Co-Rapporteur: Selma Arapovic Dzakula, PRAC Rapporteur: Rhea Fitzgerald, "Extension application to introduce a new pharmaceutical form associated with new strength (50 mg powder for concentrate for solution for injection/infusion). The new presentation is indicated to include the intravenous induction and maintenance of general anesthesia (GA) in adults for Byfavo 50 mg, based on final results from two pivotal trials: Study ONO-2745-05, a phase IIb/III, single-blind, randomised, parallel-group study assessing safety and efficacy in induction and maintenance of anaesthesia in ASA I/II patients (general surgery), and study CNS-7056-022, a phase III, randomized, propofol controlled, parallel group, confirmatory single-blind efficacy and safety trial during induction and maintenance of anaesthesia in ASA III/IV patients.
A new combined version of the SmPC, labelling and Package Leaflet solely for the 50 mg strength and the GA indication is provided accordingly.
Version 1.1 of the RMP has also been submitted.
As part of the application, the MAH also requests an extension of the market protection by one additional year."
List of Questions adopted on 19.05.2022.

**dapagliflozin - EMEA/H/C/006006**
treatment of type 2 diabetes mellitus, heart failure and chronic kidney disease
List of Questions adopted on 23.06.2022.

**sirolimus - EMEA/H/C/005896, Orphan**
Plusultra pharma GmbH, Treatment of angiofibroma associated with tuberous sclerosis complex
List of Questions adopted on 22.04.2022.

**bardoxolone methyl - EMEA/H/C/005869, Orphan**
Reata Ireland Limited, treatment of chronic kidney disease
List of Questions adopted on 24.02.2022.

**daprodustat - EMEA/H/C/005746**
treatment of anaemia associated with chronic kidney disease (CKD) in adults
List of Questions adopted on 23.06.2022.

**spironolactone - EMEA/H/C/005535**
Management of refractory oedema
List of Questions adopted on 24.03.2022.

**tremelimumab - EMEA/H/C/006016, Orphan**
AstraZeneca AB, For use in combination with durvalumab for the treatment of adults with unresectable hepatocellular carcinoma.
List of Questions adopted on 21.07.2022.

**filgrastim - EMEA/H/C/005888**
Reduction in the duration of neutropenia and the incidence of febrile neutropenia, indicated for the mobilisation of peripheral blood progenitor cells and persistent neutropenia in patients with advanced HIV infection
List of Questions adopted on 23.06.2022.

### B.6.4. Annual Re-assessments: timetables for adoption

### B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

**SIRTURO - bedaquiline - EMEA/H/C/002614/R/0050, Orphan**
Janssen-Cilag International N.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga

### B.6.6. VARIATIONS – START OF THE PROCEDURE

**Timetables for adoption** provided that the validation has been completed.

### B.6.7. Type II Variations scope of the Variations: Extension of indication

### B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

**Adjupanrix - pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - EMEA/H/C/001206/II/0079/G**
GlaxoSmithkline Biologicals SA, Informed Consent of Pandemrix (EXP), Rapporteur: Johann Lodewijk Hillege

**AMGEVITA - adalimumab - EMEA/H/C/004212/II/0031**
Amgen Europe B.V., Rapporteur: Kristina Dunder

**Cosentyx - secukinumab - EMEA/H/C/003729/II/0092/G**
Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola

**Doptelet - avatrombopag - EMEA/H/C/004722/II/0015/G**
Swedish Orphan Biovitrum AB (publ), Rapporteur: Aaron Sosa Mejia

**Foclivia - prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) - EMEA/H/C/001208/II/0079**
Seqirus S.r.l, Rapporteur: Armando Genazzani

**Imfinzi - durvalumab - EMEA/H/C/004771/II/0051**
AstraZeneca AB, Rapporteur: Aaron Sosa Mejia

**IMVANEX - smallpox vaccine (live modified vaccinia virus Ankara) - EMEA/H/C/002596/II/0079**
Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus

**Inflectra - infliximab - EMEA/H/C/002778/II/0108/G**
Pfizer Europe MA EEIG, Duplicate, Duplicate of Remsima, Rapporteur: Outi Mäki-Ikola

**Nulojix - belatacept - EMEA/H/C/002098/II/0082/G**

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson

**Reblozyl - luspatercept - EMEA/H/C/004444/II/0013, Orphan**
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Daniela Philadelphy

**Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMEA/H/C/004336/II/0059/G**
GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke

**Spikevax - elasomeran - EMEA/H/C/005791/II/0078/G**
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus

**Spikevax - elasomeran - EMEA/H/C/005791/II/0079/G**
Moderna Biotech Spain, S.L., Co-Rapporteur: Andrea Laslop

**TRODELVY - sacituzumab govitecan - EMEA/H/C/005182/II/0016/G**
Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus

**Vimizim - elosulfase alfa - EMEA/H/C/002779/II/0039, Orphan**
BioMarin International Limited, Rapporteur: Johann Lodewijk Hillege

**Vydura - rimegepant - EMEA/H/C/005725/II/0002/G**
Biohaven Pharmaceutical Ireland DAC, Rapporteur: Janet Koenig

**Xofigo - radium-223 - EMEA/H/C/002653/II/0047**
Bayer AG, Rapporteur: Janet Koenig

**WS2340/G**
**Fluenz Tetra-**
**EMEA/H/C/002617/WS2340/0119/G**
**Pandemic influenza vaccine H5N1 AstraZeneca-**
**EMEA/H/C/003963/WS2340/0053/G**
AstraZeneca AB, Lead Rapporteur: Christophe Focke

**WS2344**
**Ryzodeg-**
**EMEA/H/C/002499/WS2344/0048**

**Tresiba-EMEA/H/C/002498/WS2344/0056**
**Xultophy-**
**EMEA/H/C/002647/WS2344/0044**
Novo Nordisk A/S, Lead Rapporteur: Kristina Dunder

**WS2346/G**
**Blitzima-**
**EMEA/H/C/004723/WS2346/0059/G**
**Truxima-**
**EMEA/H/C/004112/WS2346/0062/G**
Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz

**WS2347/G**
**Infanrix hexa-**
**EMEA/H/C/000296/WS2347/0318/G**
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

### B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

**Alecensa - alectinib -**
**EMEA/H/C/004164/II/0042**
Roche Registration GmbH, Rapporteur: Filip Josephson, "Submission of the final report from study JO28928 (J-ALEX) a Randomized Phase III Open-Label Study Comparing the Efficacy and Safety of Crizotinib and CH5424802 in ALK-Positive Advanced or Recurrent Non-Small Cell Lung Cancer."

**Kesimpta - ofatumumab -**
**EMEA/H/C/005410/II/0007**
Novartis Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 5.1 and 5.2 of the SmPC in order to add information on the pharmacologic profile of ofatumumab subcutaneous administration to properly evaluate and group Kesimpta into the therapeutic landscape of Multiple Sclerosis based on feedback from the German and other HTA bodies, requiring additional information on the pharmacologic profile of ofatumumab (s.c.) to adequately inform payors and prescribers."

**Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0026/G**

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of sections 4.6, 4.8, 5.1, 5.2 and 5.3 of the SmPC in order to update the latest non-clinical virology and toxicology data, pertinent clinical pharmacology information, and final clinical efficacy and safety data from the pivotal C4671005 (REC35) study and supportive C4671002 (REC36) and C4671006.
The Package Leaflet is updated accordingly.
In addition, MAH is taking this opportunity to introduce editorial changes."

**Veklury - remdesivir - EMEA/H/C/005622/II/0042**

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Update of section 5.1 to provide in vitro data on the antiviral activity of remdesivir against the Omicron subvariants BA.2.12.1, BA.4 and BA.5 following procedure II/0034/G based on in vitro study "Remdesivir Antiviral Activity against Omicron Subvariants BA.2.12.1, BA.4 and BA.5 in A549-hACE2-TMPRSS2 Cells"."

**VEYVONDI - vonicog alfa - EMEA/H/C/004454/II/0026**

Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.8 and 5.1 of the SmPC in order to add 'headache' to the list of adverse drug reactions (ADRs) with frequency very common and to update information based on final results from study 071301 and other available data; study 071301 is a prospective, phase 3, open-label, international multicenter study on efficacy and safety of prophylaxis with rVWF in severe von Willebrand disease. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to introduce minor editorial changes to the PI and bring it in line with the latest QRD template."

**Xarelto - rivaroxaban - EMEA/H/C/000944/II/0097**

Bayer AG, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add ´eosinophilic pneumonia´ to the list of adverse drug reactions (ADRs) with frequency 'very rare', based on post-marketing data; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the

Package Leaflet.”

**WS2343**
**Ozempic-**
**EMEA/H/C/004174/WS2343/0033**
**Rybelsus-**
**EMEA/H/C/004953/WS2343/0028**
Novo Nordisk A/S, Lead Rapporteur: Johann Lodewijk Hillege, “Submission of an updated final report from study NN9535-4386 (SUSTAIN-11) in order to amend an error. This study was listed as a category 3 study in the RMP and was previously assessed in procedure EMEA/H/C/004174/II/WS/2141. This is a Phase IIIb A 52-week, multi-centre, multinational, open-label, active-controlled, two armed, parallel-group, randomised trial in subjects with type 2 diabetes to evaluate the effect of semaglutide once-weekly versus insulin aspart three times daily, both as add on to metformin and optimised insulin glargine (U100) in subjects with type 2 diabetes.”

**WS2358**
**Elebrato Ellipta-**
**EMEA/H/C/004781/WS2358/0028**
**Trelegy Ellipta-**
**EMEA/H/C/004363/WS2358/0025**
GlaxoSmithKline Trading Services Limited, Lead Rapporteur: Jayne Crowe, “Update of section 4.8 of the SmPC in order to add ‘urinary retention’ and ‘dysuria’ to the list of adverse drug reactions (ADRs) with frequency rare; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and bring it in line with the latest QRD template.”

### B.6.10. CHMP-PRAC assessed procedures

**Beovu - brolucizumab -**
**EMEA/H/C/004913/II/0018**
Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Brigitte Keller-Stanislawski, “Update of sections 4.2 and 5.1 of the SmPC in order to introduce an alternative posology regimen for wet AMD and update information based on modelling and simulation studies; the Package Leaflet is updated accordingly. The RMP version 9.0 has also been submitted.”

| | |
|---|---|
| **COMIRNATY - tozinameran - EMEA/H/C/005735/II/0143**<br>BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst"Addition of a new strain (Omicron BA.4-5) resulting in a new Comirnaty bivalent Original/Omicron BA.4-5 (15 µg / 15 µg per dose) dispersion for injection presentation. The SmPC, the Package Leaflet and Labelling are updated accordingly. The submission includes a revised RMP version 7.0." | See 9.1 and B.5.3 |
| **Ilumetri - tildrakizumab - EMEA/H/C/004514/II/0036**<br>Almirall S.A, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Adam Przybylkowski | |
| **Imnovid - pomalidomide - EMEA/H/C/002682/II/0047, Orphan**<br>Bristol-Myers Squibb Pharma EEIG, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Eva A. Segovia, "Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and PI documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan across the 3 IMiDs. These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The updated RMP version 16 was provided." | |
| **Revlimid - lenalidomide - EMEA/H/C/000717/II/0123**<br>Bristol-Myers Squibb Pharma EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and PI documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan across the 3 IMiDs. These proposed changes will only have a limited impact on the National | |

Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The MAH is also taking the opportunity to update the RMP with PASS Protocol milestones. The updated RMP version 38 was provided."

**Thalidomide BMS - thalidomide - EMEA/H/C/000823/II/0076**

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and PI documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan across the 3 IMiDs. These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The MAH is also taking the opportunity to update the RMP with PASS Protocol milestones, and to make some editorial changes in the labelling. The updated RMP version 20 was provided."

### B.6.11. PRAC assessed procedures

PRAC Led

**Kaletra - lopinavir / ritonavir - EMEA/H/C/000368/II/0193**

AbbVie Deutschland GmbH & Co. KG, PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Jean-Michel Race, "Submission of the final report from study P19-106 listed as a category 3 study in the RMP. This is a European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) observational study assessing the safety and effectiveness of Kaletra oral solution in children aged 14 days to 2 years with human immunodeficiency virus 1 (HIV-1) infection in Europe. The RMP version 10.0 has also been submitted."

PRAC Led

**Menveo - meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/001095/II/0112**

GSK Vaccines S.r.l, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 10 in order to remove several safety concerns."

PRAC Led

**NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0022**

Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on pericarditis and myocarditis and to add pericarditis and myocarditis to the list of adverse drug reactions (ADRs) with frequency not known following the outcome of MEA/014.4 based on PRAC assessment on pericarditis and myocarditis.
The Package Leaflet is updated accordingly."

PRAC Led

**Spikevax - elasomeran - EMEA/H/C/005791/II/0077**

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "Update of section 4.8 of the SmPC to include 'Acute and Delayed urticaria' as an adverse reaction, with the frequency 'Rare', as requested by the PRAC in the 13th Safety Summary Report (EMEA/H/C/005791/MEA/011.12). The Package Leaflet is updated accordingly."

PRAC Led

**SYLVANT - siltuximab - EMEA/H/C/003708/II/0038, Orphan**

EUSA Pharma (Netherlands) B.V., PRAC Rapporteur: Brigitte Keller-Stanislawski, "Submission of the report from study ACCELERATE (Advancing Castleman Care with an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for

Patients with Castleman Disease - NCT02817997 listed as an obligation in the Annex II of the Product Information.
This is a study Report to cover the data collected for 100 patients over a 5 year period in the ACCELERATE Registry study to collect information or patients with Castleman's Disease who are candidates to receive Sylvant or are currently receiving treatment with Sylvant.
The Annex II is updated accordingly."

### B.6.12. CHMP-CAT assessed procedures

### B.6.13. CHMP-PRAC-CAT assessed procedures

**Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0033/G, Orphan, ATMP**

Novartis Europharm Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege, PRAC Rapporteur: Ulla Wändel Liminga,
"Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to introduce additional guidance on liver function laboratory tests and monitoring before and after infusion and update information based on new safety information on the topic of acute liver failure (ALF) following two reports of fatal ALF.
Update of sections 4.2 and 4.4 of the SmPC in order to provide additional guidance relevant to patient's overall health status prior to dosing and to strengthen the existing description and guidance on systemic immune response.
Update of the section 4.4 of the SmPC in order to indicate prompt attention to thrombotic microangiopathy (TMA) and to reflect the risk of life-threatening or fatal outcomes.
The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to update the Annex II."

### B.6.14. PRAC assessed ATMP procedures

### B.6.15. Unclassified procedures and worksharing procedures of type I variations

**WS2243/G**

**Herceptin-**
**EMEA/H/C/000278/WS2243/0184/G**
**MabThera-**
**EMEA/H/C/000165/WS2243/0193/G**
Roche Registration GmbH, Lead Rapporteur: Jan Mueller-Berghaus

**WS2348**
**Ongentys-**
**EMEA/H/C/002790/WS2348/0052**
**Ontilyv-EMEA/H/C/005782/WS2348/0007**
Bial - Portela & Cª, S.A., Lead Rapporteur: Martina Weise

**WS2354/G**
**Abseamed-**
**EMEA/H/C/000727/WS2354/0100/G**
**Binocrit-**
**EMEA/H/C/000725/WS2354/0099/G**
**Epoetin alfa Hexal-**
**EMEA/H/C/000726/WS2354/0099/G**
Sandoz GmbH, Lead Rapporteur: Alexandre Moreau

**B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY**

**B.7.1. Yearly Line listing for Type I and II variations**

**B.7.2. Monthly Line listing for Type I variations**

**B.7.3. Opinion on Marketing Authorisation transfer (MMD only)**

**B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)**

**B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)**

**B.7.6. Notifications of Type I Variations (MMD only)**

**C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)**

**D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)**

**E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES**

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

**E.1. PMF Certification Dossiers:**

**E.1.1. Annual Update**

**E.1.2. Variations:**

**E.1.3. Initial PMF Certification:**

**E.2. Time Tables – starting & ongoing procedures: For information**

| | |
|---|---|
| PMF timetables starting and ongoing procedures | Tabled in MMD and sent by post mail (folder E). |

**F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver**

## G. ANNEX G

### G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

### G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

#### G.2.1. List of procedures concluding at 12-15 September 2022 CHMP plenary:

#### G.2.2. List of procedures starting in September 2022 for October 2022 CHMP adoption of outcomes

## H. ANNEX H - Product Shared Mailboxes – e-mail address